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SPEAKER PRESENTATIONS
O1
Male versus female breast cancer: a comparative study of 523 matched 
cases reveals diff  erences behind similarity
V Speirs1, G Ball2, Male Breast Cancer Consortium
1Leeds Institute of Molecular Medicine, Leeds, UK; 2Nottingham Trent University, 
Nottingham, UK
Breast Cancer Research 2010, 12(Suppl 1):O1 (doi: 10.1186/bcr2492)
Retrospective studies on male breast cancer (MBC) have suff  ered from small 
numbers of cases available from any one centre; thus a signifi  cant problem 
in eff  ectively studying this disease is accruing suffi   ciently large numbers to 
allow comparative analysis of biomarkers associated with response. Using a 
coordinated multicentre approach, we present the fi  rst large-scale study to 
address the relevance of the expression of hormone receptors in MBC and 
female breast cancer (FBC) using immunohistochemistry combined with a 
novel bioinformatics approach. Following ethical approval, 523 archival blocks 
(260 MBCs and 263 matched FBCs) were obtained retrospectively. Tissue 
microarrays were constructed and sections stained for ERα, ERβ1, ERβ2, ERβ5, 
total PR, PRA, PRB and AR and typed using CK5/6, CK14, CK18 and CK19 by 
immunohistochemistry. Following scoring, a range of ordination techniques 
were conducted on the datasets including hierarchical clustering and principal 
component analysis (PCA) to determine the diff  erential nature of infl  uences 
and interactions between MBC and FBC. Luminal A subgroup (ERα+ and/or PR+, 
HER2–) was the most common phenotype in both sexes. Luminal B (ERα+ and/or 
PR+, HER2+) was not seen in males, while basal-like tumours (ERα–, PR–, HER2–, 
CK5/6+) were infrequent in both. Hierarchical clustering revealed common 
clusters between MBC and FBC including total PR-PRA-PRB and ERβ1/2 clusters. 
ERα occurred on distinct clusters between males and females. AR, ERβ1, ERβ2 
and ERβ5 all existed on the same cluster but with a diff  erent substructure, 
particularly around the positioning of AR. ERα associated with this cluster in 
the male but not the female group. PCA confi  rmed that in both groups strong 
infl  uences came from PR-PRA-PRB. In MBC strong infl  uences additionally came 
from AR and ERβ1, ERβ2 and ERβ5, whereas in FBC strong infl  uences came from 
ERα alone. Our data support the hypothesis that breast cancer is biologically 
diff  erent in male and females, which could have implications for therapy.
O2
Upregulation of ADAM proteases and HER ligands through a feedback 
loop mediates acquired resistance to trastuzumab in HER2-amplifi  ed 
breast cancer
M Gijsen1, P King2, T Perera2, P Parker3, B Larijani3, A Harris1, A Kong1
1University of Oxford, UK; 2Johnson & Johnson Pharmaceutical Research & 
Development, Turnhoutseweg, Belgium; 3Cancer Research UK, London Research 
Institute, London, UK
Breast Cancer Research 2010, 12(Suppl 1):O2 (doi: 10.1186/bcr2493)
Introduction  The response rarely sustains long among the responders for 
Herceptin (trastuzumab) monotherapy treatment. It is still poorly understood 
how Herceptin exerts its mechanism of action and how the acquired resistance 
to this drug occurs.
Materials and methods We used a multidisciplinary approach including 
fl  uorescence resonance energy transfer and biochemical methods to assess 
the eff  ects of Herceptin on various signalling pathways and to determine the 
acquired resistance mechanisms of Herceptin in various HER2-positive breast 
cell lines and a BT474 xenograft model.
Results We have shown that Herceptin does not decrease HER2 phosphorylation 
despite the eff  ect on HER2 receptor downregulation. HER2 phosphorylation is 
maintained by the activation of EGFR, HER3 and HER4 via their dimerisation 
with HER2 in breast cancer cells. The activation of EGFR, HER3 and HER4 is 
induced by HER ligand release, including heregulin and betacellulin. The release 
of HER ligands is mediated by ADAM proteases including ADAM17/TACE. 
Furthermore, we demonstrated that the feedback loop involving HER ligands 
and ADAM proteases is activated due to a decrease in PKB phosphorylation 
induced by Herceptin treatment. The feedback loop is also switched on when 
PKB phosphorylation is decreased by a PKB inhibitor. We have shown that the 
feedback loop activates the HER receptors and maintains HER2 phosphorylation 
in response to Herceptin. Herceptin in combination with a panHER inhibitor also 
caused a much greater tumour inhibition compared with Herceptin or panHER 
inhibitor alone in the xenograft model.
Conclusions Our data provide evidence that Herceptin as monotherapy may 
result in poor outcome for patients due to the escape mechanisms through a 
feedback loop involving the upregulation of ADAM proteases and HER ligands. 
We have provided a novel mechanism of acquired resistance to Herceptin in 
HER2-positive breast cancer and have resolved the inconsistencies in the 
literature regarding the eff  ect of Herceptin on HER2 phosphorylation.
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New regulators of the BRCA1 response to genotoxic stress
JR Morris1, C Boutell2, M Keppler1, R Densham1, D Weekes1, A Alamshah1, 
L Butler1, Y Galanty3, L Pangon1, T Kiuchi1, T Ng1, E Solomon1
1King’s College London, UK; 2MRC Virology Unit, Glasgow, UK; 3Gurdon Institute, 
Cambridge, UK
Breast Cancer Research 2010, 12(Suppl 1):O3 (doi: 10.1186/bcr2494)
The breast and ovarian predisposition protein BRCA1 is a required component 
of the mammalian response to double-stranded DNA damage. Its conserved 
BRCT domains are required for BRCA1 accumulation to sites of repair, while 
the conserved N-terminal RING domain is able to catalyse the conjugation of 
ubiquitin and act as an E3 ubiquitin ligase. Disruption of either of these domains 
by missense mutation is associated with disease development.
The SUMO conjugation pathway has been implicated in DNA damage response 
in model organisms, and in Caenorhabditis elegans the Brac1 binding partner 
Bard1 associates with the SUMO E2 conjugating enzyme Ubc9. In mammalian 
cells, BRCA1 has been found to be associated with free SUMO-1 resulting in 
altered transcription.
We undertook to examine the potential infl  uence of the SUMO pathway on 
BRCA1 response to genotoxic stress.
Using a range of biochemical and cell-biology techniques, we have shown that 
BRCA1 is modifi  ed by SUMO in response to genotoxic stress, and co-localises at 
sites of DNA damage with SUMO1, SUMO2/3 and the SUMO conjugating enzyme 
Ubc9. PIAS SUMO E3 ligases co-localise with and modulate SUMO modifi  cation 
of BRCA1, and are required for BRCA1 ubiquitin ligase activity in cells. In vitro 
SUMO modifi  cation of the BRCA1:BARD1 heterodimer greatly increases its ligase 
activity, identifying it as a SUMO regulated ubiquitin ligase. Further, PIAS SUMO 
ligases are required for complete accumulation of double-strand DNA damage 
repair proteins subsequent to RNF8 accrual, and for profi  cient double-strand 
break repair. Because the two features of BRCA1 activity regulated by the SUMO 
pathway, ubiquitin ligase activity and accumulation at sites of DNA damage, are 
also inhibited by some BRCA1 mutations that predispose to breast cancer and 
ovarian cancer, it seems highly likely that the SUMO pathway will be of relevance 
to cancer predisposition and development.
O4
DNA methylome of familial breast cancer identifi  es distinct profi  les 
defi  ned by mutation status
JM Flanagan1,2, S Kugler3, N Waddell3, CN Johnstone3, A Marsh3, S Henderson2, 
P Simpson4, L da Silva4, K Khanna3, S Lakhani4, C Boshoff  2, G Chenevix-Trench3
1Imperial College London, UK; 2University College London, UK; 3Queensland Institute of 
Medical Research, Brisbane, Australia; 4University of Queensland, Brisbane, Australia
Breast Cancer Research 2010, 12(Suppl 1):O4 (doi: 10.1186/bcr2495)
It is now understood that epigenetic alterations occur frequently in sporadic 
breast carcinogenesis, but little is known about the epigenetic alterations 
associated with familial breast tumors. We performed genome-wide DNA 
methylation profi  ling on familial breast cancers (n = 33) to identify patterns 
of methylation specifi  c to the diff  erent mutation groups (BRCA1, BRCA2 and 
BRCAx) or intrinsic subtypes of breast cancer (basal, luminal A, luminal B, HER2-
amplifi   ed and normal-like). We used methylated DNA immunoprecipitation 
(meDIP) on Aff   ymetrix promoter chips to interrogate methylation profi   les 
across 25,500 distinct transcripts. Using a support vector machine classifi  cation 
algorithm, we demonstrated that genome-wide methylation profi  les predicted 
tumor mutation status with estimated error rates of 19% (BRCA1), 31% 
(BRCA2) and 36% (BRCAx), but did not accurately predict the intrinsic subtypes 
defi  ned by gene expression with error rates of 43% (basal) and 54% (luminal 
A). Furthermore, using unsupervised hierarchical clustering we identifi   ed a 
distinct subgroup of BRCAx tumors defi  ned by methylation profi  les. Finally, 
gene expression profi  ling and the SNP CGH array previously performed on the 
same samples allowed full integration of methylation, gene expression and copy 
number datasets. This integrated analysis revealed frequent hypermethylation 
of genes that also displayed loss of heterozygosity compared with the tumors 
that were diploid for that gene. We also observed frequent hypermethylation of 
genes that show copy number gains compared with diploid tumors providing 
a potential mechanism for expression dosage compensation. Together these 
data show that methylation profi  les for familial breast cancers are defi  ned by the 
mutation status and distinct from the intrinsic subtypes.
O5
Diff  erentiation therapy: targeting breast cancer stem cells to reduce 
resistance to radiotherapy and chemotherapy
R Roy1, PM Willan1, R Clarke2, G Farnie1
1Treatment Resistance and Cancer Stem Cell Research, University of Manchester, UK; 
2Breast Biology Group, University of Manchester, UK
Breast Cancer Research 2010, 12(Suppl 1):O5 (doi: 10.1186/bcr2496)
Studies have shown that cancer stem-like cells (CSCs) from solid cancers 
are resistant to both radiotherapy and chemotherapy. We have shown that 
primary breast cancers (n = 8) and a breast cancer cell line (MCF7) enriched for 
breast cancer stem cells (BCSC) using mammosphere (MS) clonogenic culture 
can preferentially survive radiotherapy and chemotherapy treatment in vitro, 
showing ≥50% increase in MS survival compared with non-BCSC enriched 
cells. The BCSC enriched population, defi  ned by the cell surface markers ESA+/
CD44+/CD24–/low, had reduced levels of DNA damage (measured by γH2AX) after 
4 Gy irradiation or doxorubicin (1 μM) treatment. This suggests that the BCSC 
enriched population avoids or repairs the DNA damage signifi  cantly more than 
the whole population.
Diff   erentiating agents have been used to re-sensitise breast cancers to 
endocrine treatment but eff  ects on BCSC are unknown. All-trans-retinoic acid 
(ATRA), tricostatin A and vorinostat caused a dose-dependent decrease in the 
BCSC population using MS culture and FACS analysis after 72 hours of treatment 
in a monolayer. Vorinostat (100 nM) showed the greatest eff  ect, with 80% 
reduction in the ESA+/CD44+/CD24–/low population and a 50% reduction in MS 
formation. Our data suggest that in vitro treatment with diff  erentiating agents 
reduces the number of the BCSC within the MCF7 cell line.
Combination of ATRA (2 μM) or vorinostat with 6 Gy irradiation caused a 
signifi  cant reduction in MS survival showing a 30% and 70% decrease compared 
with an irradiated control. Similarly, in combination with paclitaxel (0.5 μM) ATRA 
and vorinostat caused a signifi  cant reduction in MS survival, showing 70% and 
60% decrease compared with paclitaxel alone. In primary breast cancers (n = 3), 
combination of ATRA and 6 Gy irradiation signifi  cantly decreased MS formation 
by ≥25% respectively compared with irradiation alone.
These observations suggest that targeting BCSC with agents that eliminate or 
diff  erentiate BCSC is a promising strategy to overcome resistance to radiotherapy 
and chemotherapy in the clinic.
O6
Transforming growth factor-beta co-receptor endoglin suppresses breast 
cancer invasion and metastasis
LA Henry1, DJ Johnson1, S Lee1, PR Quinlan2, T Crook1, AM Thompson2, 
JS Reis-Filho1, CM Isacke1
1Institute of Cancer Research, London, UK; 2Ninewells Hospital and Medical School, 
Dundee, UK
Breast Cancer Research 2010, 12(Suppl 1):O6 (doi: 10.1186/bcr2497)
Transforming growth factor-beta (TGFβ) signaling in cancer has been implicated 
in both growth suppression in early lesions as well as enhancing tumor cell 
invasion and metastasis. However, the cellular mechanisms that determine the 
signaling output in individual tumors are still largely unknown. In endothelial 
cells, TGFβ signaling is modulated by the TGFβ co-receptor endoglin (CD105). 
Here we demonstrate that endoglin is diff  erentially expressed in invasive breast 
cancers and breast cancer cell lines, and is subject to epigenetic silencing by 
gene methylation. Downregulation of endoglin expression in nontumorigenic 
MCF10A cells leads to the formation of abnormal acini in 3D culture but does 
not promote cell migration or result in cell transformation. In contrast, in the 
presence of an activated oncogene, loss of endoglin in MCF10A cells leads to 
enhanced migration and invasion into a 3D matrix. Consistent with these data, 
ectopic expression of endoglin in the endoglin-negative MDA-MB-231 cell 
line blocks TGFβ-enhanced cell motility and invasion and reduces the ability 
of cells to successfully colonize the lung parenchyma in an in vivo metastasis 
model. Unlike endothelial cells, endoglin does not does not modulate canonical 
TGFβ signaling in breast cells but attenuates the cytoskeletal remodeling to 
impair cell migration and invasion. Importantly, lack of endoglin expression in 
clinical samples signifi  cantly correlates with ENG gene methylation and poor 
clinical outcome. Together these data identify endoglin as a key component 
suppressing the invasive activities of breast cancer cells.
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P1
Activin B functions downstream of BRCA1 in stem cell maintenance
MM Murray, N Buckley, DP Harkin
CCRCB, Queen’s University Belfast, UK
Breast Cancer Research 2010, 12(Suppl 1):P1 (doi: 10.1186/bcr2498)
Introduction The cancer stem cell hypothesis proposes that tumors contain 
a subset of stem or progenitor cells that are resistant to chemotherapy and 
have evaded the normally tight control of self-renewal. BRCA1 is known to play 
an essential role in cancer stem cell maintenance and diff  erentiation. In fact, 
breast tissue from women with germline mutations in BRCA1 show regions of 
increased ALDH1 positivity, a marker of stem cells. Furthermore, knockdown of 
BRCA1 in normal tissue from reduction mammoplasty leads to increased ALDH1 
and increased stem cell number as assessed by mammosphere formation.
Activin B is a secreted protein that is a member of the TGFβ family. It is a 
homodimer of inhibin βB that is expressed in various tissues and has numerous 
functions, including regulation of gonadal function, proliferation, metastasis, 
diff  erentiation and stem cell maintenance.
Results Inhibin βB was identifi  ed as a transcriptional target of BRCA1 in SKBR7 
cells on an Almac Breast-specifi  c microarray. The target was analysed in several 
breast cell lines and shown to be repressed in basal-like, but not luminal, cell lines 
following BRCA1 knockdown or reconstitution. Chromatin immunoprecipitation 
analysis showed that BRCA1 is present on the INHBB promoter. Furthermore, loss 
of BRCA1 reduced the amount of secreted protein, which in turn correlated with 
reduced activation of the TGFβ pathway as shown by reduced phosphorylation 
of Smad2.
We have stably knocked down BRCA1 in MCF10A cells which, as expected, 
increased stem cell numbers in comparison with control cells as assessed by 
mammosphere formation and Aldefl  uor postivity. This defect can be rescued 
by addition of recombinant activin B or mimicked by inhibiting activin B activity 
with follistatin or SB-431542.
Conclusions We have identifi  ed inhibin βB as a novel transcriptional target 
of BRCA1 in basal-like cell lines. Preliminary phenotypic studies indicate that 
the homodimer of inhibin βB, activin B, functions downstream of BRCA1 in 
regulating stem cell numbers.
P2
FOXM1 is a transcriptional target of ERα and has a critical role in breast 
cancer endocrine sensitivity and resistance
J Millour, EW Lam
Imperial College London, UK
Breast Cancer Research 2010, 12(Suppl 1):P2 (doi: 10.1186/bcr2499)
Previous data have shown that FOXM1 expression is elevated in breast cancer 
tissues and is strongly correlated with the expression pattern of ERα in breast 
cancer cells. The expression of ERα is a good prognostic factor in breast cancer, 
as about two-thirds of these ERα-positive patients respond to treatment with 
antiestrogens. However, approximately one-half of the patients that initially 
respond to hormonal therapy develop resistance. Since FOXM1 is critical for 
the progression of the cell cycle, we investigated the regulation of FOXM1 by 
ERα and its role in endocrine sensitivity and resistance in breast cancer cells. 
We fi  rstly observed by quantitative RT-PCR a strong and signifi  cant positive 
correlation between ERα and FOXM1 mRNA expression in breast cancer patient 
samples. We showed that FOXM1 protein and mRNA expression was regulated 
by ER ligands. We also demonstrated that ectopic conditional expression of 
ERα, in the presence of estrogens, leads to induction of FOXM1 expression in 
ER-negative U2OS cells. Using reporter gene assays, we demonstrated that ERα 
activates FOXM1 transcription through an estrogen-response element site. The 
direct binding of ERα to the FOXM1 promoter was confi  rmed in vitro by mobility 
shift and DNA pull-down assays and in vivo by chromatin immunoprecipitation 
analysis. Importantly, silencing of FOXM1 by RNA interference abolishes the 
estrogen-mediated MCF-7 cell proliferation. Conversely, ectopic expression of 
a constitutively active FOXM1 can abrogate the cell cycle arrest mediated by 
the antiestrogen tamoxifen. Taken together, the results clearly demonstrate 
FOXM1 as a key mediator of the mitogenic functions of ERα and estrogen in 
breast cancer cells. Our fi  ndings that antiestrogens repress FOXM1 expression in 
endocrine-sensitive but not endocrine-resistant breast carcinoma cell lines and 
that ectopic expression of an active FOXM1 can abrogate the anti-proliferative 
eff   ects of tamoxifen also suggest that deregulation of FOXM1 may also 
contribute to antiestrogen insensitivity.
P3
A novel and selective PDK1 inhibitor reduces breast cancer cell invasion 
and tumour growth
C Raimondi1, T Maff  ucci1, BVL Potter2, M Falasca1
1Queen Mary University of London, UK; 2University of Bath, UK
Breast Cancer Research 2010, 12(Suppl 1):P3 (doi: 10.1186/bcr2500)
Impairment of metastasis development is a critical target for cancer therapy. We 
recently reported that phospholipase Cγ1 (PLCγ1) is involved in regulation of 
motility and invasion of cancer cells and is required for metastasis development 
and progression. Experimental metastasis assays in nude mice revealed that 
inducible knockdown of PLCγ1 strongly inhibits development of MDA-MB-
231-derived lung metastasis and reverts metastasis formation. In an eff  ort 
to develop anti-metastatic drugs, diff  erent inositol phosphates compounds 
were tested to identify potential PLCγ1 inhibitors. We found that a synthetic 
derivative of inositol pentakisphosphate, Ins(1,3,4,5)P5, inhibits cell migration 
and 3D invasion in MDA-MB-231 and MDA-MB-435 human breast cancer cell 
lines and in TSA murine mammary adenocarcinoma cells and reduces calcium 
release upon EGF stimulation indicating a potential inhibition on PLCγ1 activity. 
Kinase profi  le assay, performed in vitro to test the potential inhibitory eff  ect of 
the Ins(1,3,4,5)P5 synthetic derivative on diff  erent kinases showed a specifi  c 
inhibition of the 3-phosphoinositide-dependent-protein kinase 1 (PDK1) with an 
IC50 of 26 nM. Knockdown of PDK1 using the small interfering RNA technology 
in breast cancer cell line MDA-MB-231 showed an impairment in cell migration 
and invasion and inhibition of EGF-induced calcium mobilisation. In addition, 
it has been recently shown that PDK1 is a critical determinant for resistance to 
tamoxifen anti-cancer drug. Our experiments show that combined treatment of 
the Ins(1,3,4,5)P5 synthetic derivative with tamoxifen, paclitaxel, and curcumin 
in MCF7 and MDA-MB-468 cells results in additive or more than additive eff  ects, 
and therefore suggest that this novel PDK1 inhibitor can be potentially used in 
combination with other drugs to increase their anti-cancer activity.
P4
Regulation of mammary epithelial architecture by PTEN
JC Lim, L Davidson, NR Weerasinghe, G Zilidis, P Tibarewal, L Spinelli, NR Leslie
University of Dundee, UK
Breast Cancer Research 2010, 12(Suppl 1):P4 (doi: 10.1186/bcr2501)
The PTEN tumour suppressor is a core component of the phosphoinositide 
3-kinase (PI3K) signalling pathway. PTEN is mutated, deleted, or otherwise 
silenced in over one-third of breast cancers, with another one-third carrying 
other activating mutations in the core PI3K signalling pathway, most of these 
being activating mutations in the p110α catalytic subunit of PI3K itself. The 
best characterised tumour suppressor roles for PTEN are the suppression of 
cell growth, survival, proliferation and metabolic deregulation. However, we 
have found that in three-dimensional cultured mammary epithelial cells, 
knockdown of PTEN leads to the loss of cell polarity and tissue architecture. 
PTEN knockdown also causes a dramatic disruption of normal tight junction 
formation in adherent mammary epithelial cell cultures. Since the deregulation 
of cell polarity is becoming recognised as a potential driving force behind the 
formation of some tumours, we have been further studying the mechanisms by 
which PTEN controls mammary epithelial cell polarity.
P5
Genetic analysis of lobular carcinoma in situ and associated invasive 
lobular cancer
LR Yates1, A Jones2, H Patel3, A Mackay4, C Gillett1, S Pinder5, I Tomlinson2, 
R Roylance3, EJ Sawyer5
1King’s College, London, UK; 2Wellcome Trust Centre for Human Genetics, Oxford, 
UK; 3Bart’s and the London School of Medicine, London, UK; 4Institute of Cancer 
Research, London, UK; 5Guy’s and St Thomas’ NHS Trust, London, UK
Breast Cancer Research 2010, 12(Suppl 1):P5 (doi: 10.1186/bcr2502)
Objectives This is a pilot study to assess the feasibility of performing SNP-loss 
of heterozygosity (LOH) on micro-dissected formalin-fi  xed paraffi   n-embedded 
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S3(FFPE)  lobular carcinoma in situ (LCIS) tissue and to examine the genetic 
relationship between LCIS and associated invasive lobular carcinomas (ILC).
Introduction LCIS is a risk factor for the development of subsequent invasive 
breast carcinoma in either breast. Approximately 50 to 70% of these subsequent 
cancers are ILC. Not all LCIS progresses to invasive disease, and at present there 
are no biomarkers that predict which cases will develop ILC.
Methods LCIS and ILC samples were microdissected from FFPE tissue blocks. 
Genetic changes were studied using SNP-LOH (Goldengate Assay; Illumina) 
to assess CN-LOH and copy number changes. Copy number changes were 
confi  rmed using 32k BAC arrays. Ploidy was assessed using Feulgen staining.
Results  SNP-LOH was successful in 31/35 samples. LOH events were more 
common in classical LCIS with associated ILC compared with pure LCIS. 
Commonest changes were on 16q and 1q. Other areas of LOH were more 
common in LCIS associated with ILC but did not reach statistical signifi  cance. 
Patterns of genetic change were maintained in ILC compared with the 
associated LCIS and 3/5 cases acquired additional genetic changes. Copy 
number changes were confi  rmed in three cases using BAC arrays. Concordance 
for copy number gain and loss was 50% and 75%, respectively. Concordance for 
copy neutral LOH was 100%. Ploidy studies on 20 cases revealed that all cases 
of classical LCIS were diploid whereas 5/9 pleomorphic LCIS/ILC samples were 
tetraploid or aneuploid.
Conclusions It is feasible to perform SNP-LOH on small amounts of micro-
dissected FFPE LCIS tissue. The pattern of genetic changes confi  rms the fi  ndings 
of others that LCIS is a likely precursor of ILC. Further investigation of genetic 
changes in LCIS associated with ILC is expected to lead to the identifi  cation of 
biomarkers that predict for subsequent invasive transformation.
P6
Suppression of the NF-κB co-factor, Bcl3, delays the metastatic 
progression of breast cancer
AM Wakefi  eld, RWE Clarkson
Cardiff   University, Cardiff  , UK
Breast Cancer Research 2010, 12(Suppl 1):P6 (doi: 10.1186/bcr2503)
A large proportion of breast cancers overexpress the HER receptors, HER1 or 
HER2. Generally these patients have a poor prognosis, exhibit resistance to fi  rst-
line anti-cancer drugs, and frequently develop metastatic disease – the most 
common cause of patient death. NF-κB transcription factors lie downstream of 
HER1/2 signalling pathways and are aberrantly activated in the majority of these 
breast tumours.
We have found that a constitutive defi  ciency in Bcl3 (an NF-κB co-factor that 
modifi  es NF-κB signalling) delayed HER2 (ErbB2) tumour onset and inhibited 
metastasis of mammary tumours in mice while growth of primary tumours was 
unaff  ected. In those Bcl3-null animals that did acquire metastases, the size of 
secondary tumours was signifi  cantly reduced compared with controls. Critically, 
Bcl3 defi  ciency did not aff  ect normal mammary function other than having a 
transitory eff  ect on apoptosis of epithelial cells in the post-lactational mammary 
gland. Therefore, unlike other NF-κB regulators, Bcl3 exhibited tumour-specifi  c 
eff  ects in vivo. The pro-metastatic properties of Bcl3 were confi  rmed in several 
human breast cancer cell lines exhibiting elevated HER2 and/or HER1 levels, 
including aggressive basal-like tumour cell types.
These observations are signifi  cant because they suggest it may be possible 
to target Bcl3 in established tumour cells to reduce metastatic behaviour, 
and furthermore that Bcl3’s eff  ects are not restricted to ERBB2-positive breast 
tumours, consistent with the observed increase in NF-κB activity seen in both 
ERBB1-positive and ERBB2-positive breast tumours.
P7
Identifi  cation of signalling pathways downstream of BRCA1 and p63
N Crawford, N Buckley, C Nic An tSaoir, D Tkocz, Z D’Costa, L Oram, P Mullan
Queen’s University Belfast, UK
Breast Cancer Research 2010, 12(Suppl 1):P7 (doi: 10.1186/bcr2504)
BRCA1 was identifi  ed in 1994 as one of the genes predisposing to early-onset 
breast and ovarian cancer. It is currently estimated that 5 to 10% of all breast and 
ovarian cancer cases are inherited and the breast cancer susceptibility genes, 
BRCA1 and BRCA2, have been identifi  ed as being responsible for up to 21 to 40% 
of these cases. Although the exact function of BRCA1 remains to be defi  ned, roles 
in DNA damage repair, cell cycle checkpoint control, transcriptional regulation 
and, more recently, ubiquitination have been inferred. p63 was identifi  ed as a 
positively regulated BRCA1 target gene through microarray analysis, and the 
functional signifi  cance of the BRCA1/p63 signalling axis was investigated.
Knockdown of BRCA1 and p63 leads to enhanced proliferation of breast cancer 
cell lines and increased stem cell numbers as assayed for by mammosphere 
culture and Aldefl  uor assay. Expression of BRCA1 or p63 in a background of low 
BRCA1 and p63 results in decreased cell proliferation. We therefore examined 
co-regulated targets of BRCA1 and p63 mediating growth control. S100A2, a 
tumour suppressor, is a known p63 target. Knockdown of BRCA1 and p63 leads 
to the loss of S100A2 expression. BRCA1 and p63 were found to be localised 
to the S100A2 promoter by chromatin immunoprecipitation assay. Loss of p63 
resulted in recruitment of BRCA1 to the S100A2 promoter. In a p63 and BRCA1 
null background, expression of S100A2 results in a reduction of cell proliferation. 
Conversely, loss of S100A2 in a BRCA1 and p63 expressing background leads to 
increased proliferation.
We have explored the regulation of signalling pathways by p63 and BRCA1 
that are involved in growth control, diff  erentiation and stem cell regulation. We 
will identify potential regulators of these pathways using microarray analysis to 
elucidate p63 and BRCA1 co-regulated targets.
P8
D133P53, directly transactivated by p53, prevents p53-mediated 
apoptosis without inhibiting p53-mediated cell cycle arrest
M Aoubala, F Murray-Zmijewski, M Khoury, S Perrier, K Fernandes, AC Prats, 
D Lane, JC Bourdon
University of Dundee, UK
Breast Cancer Research 2010, 12(Suppl 1):P8 (doi: 10.1186/bcr2505)
We recently reported that the human p53 gene encodes at least nine 
diff  erent p53 isoforms, two of which (p53β and Δ133p53) can modulate p53 
transcriptional activity and apoptosis. In the present study, we aimed to 
investigate the regulation of Δ133p53 isoform expression and the physiological 
role of Δ133p53 in modulating p53 activities.
We report that in response to genotoxic stress, p53 transactivates directly the 
human p53 internal promoter inducing Δ133p53 protein expression, which by 
diff  erentially modulating p53 target gene expression prevents p53-mediated 
apoptosis without inhibiting cell cycle arrest. This indicates that Δ133p53 does 
not simply act at physiological level in a dominant-negative manner towards 
any p53 targets, but rather modulates p53 transcriptional activity in a promoter 
and stress-dependent manner. Hence, we have established a novel feedback 
pathway that modulates the p53 response, which might have an impact on p53 
tumour suppressor activity. These observations may provide some explanations 
for the diffi   culties in many clinical studies of associating p53 status with cancer 
treatment and clinical outcome. Therefore, it would be interesting to determine 
whether Δ133p53 expression is associated with tumour markers, clinical 
outcome and cancer treatment in human cancers.
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Introduction CUB and Sushi multiple domain protein 1 (CSMD1) is a candidate 
tumour suppressor gene of unknown function. CSMD1 maps to chromosome 
8p23, a region deleted in 50% of breast cancers (BC). We have examined the 
contribution of CSMD1 to the tumorigenic phenotype of mammary acini and 
evaluated its prognostic value in BC patients.
Materials and methods A shRNA CSMD1 MCF10A three-dimensional matrigel 
model was established. Moreover, functional assays were performed using 
shCSMD1 cell lines. CSMD1 was tested by immunohistochemistry in 275 BC 
samples.
Results Loss of CSMD1 in the MCF10A three-dimensional model resulted in an 
increased number of acini (P = 0.001), which are also larger in size (40%, P = 0.02) 
and misshapen relative to the control. Although expressing a high level of active 
caspase 3, shCSMD1 acini failed to form lumen.
Loss of CSMD1 expression caused a 56% (P = 0.001) increase in proliferation and 
a 44% (P = 0.0006) decrease in adhesion. shCSMD1 cells migrate much faster 
than control cells and showed 33% (P <0.001) increase in invasion. These results 
were confi  rmed in two other cell lines.
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was associated with high tumour grade (P = 0.003) and low overall survival 
(HR = 0.607, 95% CI = 0.4 to 0.91, P = 0.018). Moreover, CSMD1 is an independent 
predictor of overall survival (HR = 0.607, 95% CI = 0.4 to 0.91, P = 0.018) [1].
Conclusions Loss of CSMD1 aff  ects cell adhesion, proliferation, migration and 
invasion, which lead to disruption of mammary duct formation. Loss of CSMD1 
is associated with poor prognosis in BC, suggesting its use as a new prognostic 
biomarker.
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The phosphoinositide 3-kinase (PI3K) family comprises eight mammalian 
isoforms grouped into three classes. Accumulating evidence suggests that 
the class II isoform PI3K-C2β may play a role in cancer development [1-3]. 
Indeed PI3K-C2β expression has been found increased in several cancers by 
gene expression profi  ling. Previou  sly, we have identifi  ed a role for PI3K-C2β 
in cancer cell migration [3]. Here we show that PI3K-C2β is overexpressed 
in several human breast cancer cell lines as compared with normal breast 
cells. Downregulation of PI3K-C2β expression by shRNA inhibits oestradiol-
dependent and heregulin-dependent growth of MCF-7 and T47D cells and soft-
agar colony formation. Immunohistochemistry analysis of breast cancer tissues 
from 90 patients revealed that PI3K-C2β is not expressed in normal portions of 
breast tumour specimens (used as internal controls) and follicular breast tissues, 
whereas it is highly expressed in infi  ltrating ductal carcinoma breast cancer 
tissues. Interestingly, we found a highly positive signifi  cant (Spearman’s rho test, 
P = 0.002) association between PI3K-C2β expression and the proliferative status 
(Ki67) of tissues analysed. In addition, we compared the expression levels of 
PI3K-C2β in 20 primary-metastasis pairs from breast cancer patients. We found 
that PI3K-C2β expression is signifi  cantly increased in lymph node metastasis 
with primary tumours (Wilcoxon–Mann–Whitney test, P = 0.001). Taken together 
these data suggest a correlation between PI3K-C2β expression and activation 
and breast cancer progression, and identify a novel molecular target.
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ERβ1 is often downregulated in cancer compared with normal cells, suggesting 
that it may function as a tumour suppressor and could play an important role 
in carcinogenesis. The expression of ERβ1 is regulated by multiple mechanisms 
such as methylation. Five splice variants of ERβ mRNA have been identifi  ed, ERβ1 
to ERβ5. However, it is unclear whether and how the full-length version, ERβ1, is 
regulated post-transcriptionally.
MicroRNAs are a class of nonprotein coding small RNAs that regulate 
expression of genes at post-transcriptional levels. Using rapid amplifi  cation of 3΄ 
complementary DNA ends (3΄RACE), we have confi  rmed 3΄ untranslated region 
(3΄UTR) expression and sequences of ERβ1 mRNA in MCF-7 cells. Based on miRNA 
expression profi  ling of human breast cancer studies, we found that miR-92 is 
upregulated in malignant breast. In silico analysis using the miRGen database 
and RNA hybrid predicted that there are two putative miR-92 target sequences 
within the 3΄UTR of human ERβ1 mRNA. Firstly, we profi  led the expression of 
ERβ1 mRNA and miR-92 in breast cancer tissue and cell lines. miR-92 levels were 
higher in ERβ1-negative MDA-MB-453 cells than ERβ1-positive MCF-7 cells. We 
observed miR-92 upregulation in breast tumours while ERβ1 mRNA expression 
was decreased compared with matched adjacent normal tissues. We found a 
signifi  cant negative correlation between miR-92 and ERβ1 mRNA and protein in 
breast tumour (r = –0.5, P = 0.001 and r = –0.39, P = 0.037), respectively.
Transfection of MCF-7 cells with anti-miR-92 increased endogenous ERβ1 mRNA 
and reduced cell proliferation. EGFP report experiment also confi  rms that the 
3΄UTR of ERβ1 carries the directly binding sites of miR-92. Finally, we showed that 
miR-92 expression is modulated by the ER ligands 17β-estradiol and tamoxifen 
in MCF-7 cells. These fi  ndings prove that ERβ1 expression is negatively regulated 
at a post-transcriptional level by miR-92. This miRNA could be considered a 
potential therapeutic target in breast cancer.
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CTCF is a highly conserved and ubiquitous transcription factor with versatile 
functions. We previously demonstrated that elevated protein levels of CTCF in 
breast cancer cells were associated with the specifi  c anti-apoptotic function of 
CTCF. We used proteomics and microarray approaches to identify regulatory 
targets of CTCF specifi  c for breast cancer cells. Among the CTCF identifi  ed 
targets were proteins involved in the control of apoptosis. A proapoptotic 
protein, Bax, negatively regulated by CTCF, was chosen for further investigation. 
Repression of the human Bax gene at the transcriptional level by CTCF in breast 
cancer cells was confi  rmed by real-time PCR. Two CTCF binding sites within 
the Bax promoter were identifi  ed by electrophoretic mobility shift assay and 
footprinting. In reporter assays, the Bax–luciferase reporter construct, containing 
CTCF-binding sites, was negatively regulated by CTCF. In vivo, CTCF occupied 
its binding sites in breast cancer cells and tissues, as confi  rmed by chromatin 
immunoprecipitation assay. Our fi   ndings suggest a possible mechanism of 
the specifi  c CTCF anti-apoptotic function in breast cancer cells whereby CTCF 
is bound to the Bax promoter, resulting in repression of Bax and inhibition of 
apoptosis; depletion of CTCF leads to activation of Bax and apoptotic death. 
CTCF binding sites in the Bax promoter are unmethylated in all cells and tissues 
inspected. Therefore, specifi  c CTCF interaction with the Bax promoter in breast 
cancer cells, and the functional outcome, may depend on a combination of 
epigenetic factors characteristic for these cells. Interestingly, CTCF appears to 
be a negative regulator of other proapoptotic genes (for example, Fas, Apaf-1, 
TP531NP1). Conversely, stimulating eff  ects of CTCF on the anti-apoptotic genes 
(Bcl-2, Bag-3) have been observed. Taken together, these fi  ndings suggest that 
specifi  c mechanisms have evolved in breast cancer cells to protect them from 
apoptosis; regulation of apoptotic genes by CTCF appears to be one of the 
resistance strategies.
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breast cancer cells to heregulins
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We have previously reported that induction of EGFR and erbB2 in response to 
antihormones may provide an early mechanism allowing breast cancer cells 
to evade the growth inhibitory action of such therapies and ultimately drive 
resistant growth. More recently, another member of the erbB receptor family, 
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present study we have investigated whether induction of erbB3, and related 
family member erbB4, may provide an alternative resistance mechanism 
to antihormonal action in a panel of four ER-positive breast cancer cell lines. 
MCF-7, T47D, BT474 and MDAMB361 cell lines were exposed to fulvestrant (100 
nM) for 7 days, and eff  ects on erbB3/4 signalling and growth were assessed. 
Eff  ects of the erbB3/4 ligand heregulin-β1 were also examined in the absence 
and presence of fulvestrant. Fulvestrant potently reduced ER expression and 
transcriptional activity and signifi  cantly inhibited growth in all four cell lines. 
However, alongside this inhibitory activity, fulvestrant also consistently induced 
protein expression and activity of erbB4 in the four cell lines and also promoted 
erbB3, erbB2 and EGFR protein expression and activity in MCF-7 and T47D cells. 
Consequently, fulvestrant treatment sensitised each cell line to the actions of 
heregulin-β1 with enhanced erbB3/4-driven signalling activity and signifi  cant 
increases in cell proliferation being observed when compared with untreated 
cells. Indeed, in T47D and MDAMB361, heregulin-β1 was converted from a ligand 
having negligible or suppressive growth activity into one that potently promoted 
cell proliferation. Consequently, fulvestrant-induced growth inhibition was 
completely overridden by heregulin-β1 in all four cell lines. In conclusion, these 
fi  ndings would suggest that although antihormones, such as fulvestrant, may 
have potent acute growth inhibitory activity in ER-positive breast cancer cells, their 
ability to induce and sensitize cells to growth factors, such as heregulins, may serve 
to reduce and ultimately limit their inhibitory activity.
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Introduction Mutations in BRCA1 and BRCA2 confer high lifetime risks of breast 
cancer. Previous studies have suggested, following an initial diagnosis, the risk 
for a contralateral breast cancer is approximately 3% annually or up to 40% at 10 
years. The results presented here are of contralateral breast cancer risk in BRCA1/
BRCA2 mutation carriers.
Methods Three hundred and seventy-four BRCA1 mutation carriers and 346 
BRCA2 mutation carriers were followed up for up to 30 years following breast 
cancer diagnosis. The incidence of a contralateral breast cancer and the eff  ect of 
tamoxifen use and oophorectomy on this were observed.
Results Follow-up over a 25-year to 30-year period shows a constant 2% annual 
risk of contralateral breast cancer in BRCA1/BRCA2 mutation carriers. This risk is 
not aff  ected by age at diagnosis of fi  rst breast cancer. Over the follow-up period, 
oophorectomy, if performed below the age of 45 years, led to a reduction in 
contralateral breast cancer risk of 40%. Tamoxifen use was shown to reduce the 
risk of a contralateral breast cancer in the fi  rst 6 years following initial diagnosis 
but no eff  ect was seen after this period. Over the full follow-up period, tamoxifen 
use did not signifi  cantly reduce the risk.
Conclusions Women who carry a BRCA1/BRCA2 mutation who have had breast 
cancer have a constant increased risk of a second contralateral breast tumour. 
Oophorectomy has a greater impact on reducing this risk than tamoxifen use.
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The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) 
family are a group of 19 extracellular, secreted proteases whose known functions 
include processing of procollagen molecules, cleavage of extracellular matrix 
proteoglycans and anti-angiogenesis. Our previous studies have shown that 
ADAMTS15 is a novel predictor of good prognosis in breast cancer; patients whose 
tumours had high levels of ADAMTS15 expression had an increased relapse-free 
survival compared with those with lower levels [1]. ADAMTS15 has also emerged 
as a candidate cancer gene from cancer genome sequencing, and its tumour 
suppressive function has recently been documented in colorectal cancer [2].
Our study has focused on the cellular eff  ects of overexpression in MCF7 and 
MDA-MB-231 breast cancer cell lines of full-length wild-type ADAMTS15 
and an E-A mutant that lacks metalloproteinase activity. We have generated 
stable transfectants carrying either an inducible (lentivirus tet-off    system) 
or constitutive vector system. The eff   ects on cell adhesion, migration and 
proliferation have subsequently been analysed. Proliferation (MTT assay) and 
adhesion to various matrix components (including collagen, fi  bronectin and 
laminin) was not altered with the addition of ADAMTS15. However, ectopic 
expression (inducible and constitutive) of either full-length ADAMTS15 or the 
catalytically dead mutant signifi   cantly reduced migration in both cell lines. 
Wild-type ADAMTS15 also enhanced the aggregation of MCF7 cells. These data 
suggest that ADAMTS15 may exert tumour suppressive eff  ects via modulation of 
the interactions of breast carcinoma cells with their environment independent 
of its metalloproteinase activity.
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Objective There is evidence to support the view that infl  ammatory processes are 
important in the development of local progression and metastases in patients 
with breast cancer. The sphingosine kinase-1/sphingosine-1-phosphate (SK1/
S1P) pathway, which is a known mediator of infl  ammation, is critically implicated 
in breast cancer progression and chemotherapy resistance and is linked with 
poor prognosis. In this study we have investigated the implication of the SK1/
S1P pathway in the interaction between tumour-associated macrophages and 
breast cancer cells.
Methods We have used modifi  ed Boyden chambers to perform macrophage-
tumour cell co-culturing. Cytokine production and alterations in gene expression 
were measured by quantitative RT-PCR. Proteome profi  ler assays were used to 
identify secreted cytokines. Cell motility and chemotaxis were assayed in 96-well 
plates of Dunn chambers respectively using high-throughput video time-lapse 
scanning microscopy.
Results MDA-MB-231 breast cancer cells were pretreated with docetaxel and 
subsequently co-cultured with THP-1 macrophages. Macrophages exhibited 
increased chemotaxis towards apoptotic tumour cells (aTCs) or aTC conditioned 
media. Co-culturing with aTCs has transiently increased macrophage SK1 activity. 
Proteome profi  ling of media from macrophages revealed that aTCs induced an 
SK1-mediated secretion of IL-6 and siCAM-1. Interestingly, co-culturing with 
macrophages increased aTC chemoresistance. Incubation of untreated cancer 
cells with macrophages pretreated with conditioned media from aTCs induced 
an IL-6-mediated upregulation of cancer cell SK1 expression in cancer cells, 
which has lead to an increase in cancer cell motility and chemotaxis in gradients 
of macrophage conditioned media. These enhanced migratory phenotypes 
were reversed following treatment of cancer cells with SK1 siRNA.
Conclusions Our results suggest a novel IL-6/SK1-dependent mechanism of 
macrophage-induced breast cancer chemoresistance and metastasis.
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PLU-1/Jarid1B contributes to estrogen-induced cell proliferation in 
the normal mammary gland and in breast cancer, and is required for 
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PLU-1/Jarid1B is a nuclear protein that is widely expressed in breast cancer, with 
higher levels being seen in ER+ cancers. Expression in normal adult issues is 
largely restricted to testis and the diff  erentiating mammary gland. Through the 
JmjC domain the protein can demethylate H3K4me3, which correlates with its 
function as a transcriptional repressor. PLU-1/Jarid1B contains a DNA binding 
domain, and can be recruited to DNA through binding to transcription factors. 
We now fi  nd that the protein interacts with the ERα receptor and contributes to 
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tumours in nude mice.
To investigate the function of Plu-1/Jarid1B in vivo, transgenic mice expressing 
defective Plu-1/Jarid1B have been developed. The systemic KO is an embryonic 
lethal with no homozygote embryos being detected at day 7.5. Another strain 
expressing the protein missing the ARID AT-rich DNA binding domain (which 
is also required for demethylase function) shows a mammary phenotype. In 
these ΔARID mice, the development of the mammary tree at puberty and early 
pregnancy is delayed, but the gland recovers by late pregnancy. The inhibition 
of development of terminal end buds at puberty, which is crucially dependent 
on ERα signalling, suggests an involvement of Plu-1/Jarid1B in this signalling 
that is impaired in the ΔARID mouse. Confi  rming this, levels of expression of 
downstream targets of ERα (progesterone receptor and Wnt4) are reduced in 
the ΔARID mouse. The development of spontaneous mammary tumours in the 
ΔARID mouse is delayed compared with wild-type mice, suggesting that Plu-1/
Jarid1B contributes to tumour growth, and that this action is impaired when the 
ARID domain is deleted.
The data suggest that PLU-1/JARID1B is involved in estrogen-induced growth of 
normal and malignant mammary epithelial cells.
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We are interested in fi   nding novel therapeutic targets for breast cancer, 
particularly focusing on C-terminal binding proteins (CtBPs) as when they are 
inhibited, cells show an increased sensitivity to apoptotic stimuli. Using siRNA to 
inhibit CtBP expression, we have found that CtBPs are essential for the survival of 
breast cancer cells, and in particular those with a more aggressive p53-mutant 
phenotype. To direct our future studies into therapeutic strategies targeting 
CtBPs in breast cancer, we need to know more precisely how their loss results in 
death, and which of their functions are required for this prosurvival role.
Here we show that loss of CtBP function through siRNA treatment suppresses 
proliferation through a combination of p53-independent apoptosis, reduction 
in cell-cycle progression into mitosis, and aberrations in transit through mitosis 
itself. This third phenotype includes errors in mitotic chromosome segregation, 
activation of, but failure to sustain, the spindle assembly checkpoint, decreased 
expression of Aurora B, and a high rate of failure to complete cytokinesis. We 
showed that loss of CtBP in breast cancer cells with a functional p53 response 
pathway resulted in a marked upregulation of the p53 protein. Here p53 appears 
to be providing a protective role by arresting aberrant cells in G1, thus preventing 
them from entering S-phase with incorrectly segregated DNA.
CtBPs are known to act in the nucleus as transcriptional co-repressors and in 
the cytoplasm as regulators of Golgi fi  ssion. Using a series of dominant negative 
CtBP mutants microinjected into either the cytoplasm or nucleus, we show 
that localisation of CtBPs to the nucleus is critical for its function in ensuring 
the correct division of breast cancer cells. This suggests that CtBPs function in 
maintaining mitotic fi  delity, and thus in the continued proliferation and survival 
of breast cancer cells through their actions as a transcriptional co-repressor 
within the nucleus.
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Introduction Rho GTPases have multiple roles in cancer. We are working to 
characterise the novel Rho GTPase RhoBTB2/DBC2, which has been reported to 
be a tumour suppressor in breast cancer.
Materials and methods We used siRNA to mimic the loss of RhoBTB2 
expression in breast cancer and then microarray analysis to identify the gene 
targets of RhoBTB2.
Results  Screening identifi   ed the homeostatic chemokine CXCL14/BRAK as 
a target of RhoBTB2. CXCL14 is highly expressed by normal epithelial cells; 
however, its expression is downregulated in a wide range of carcinomas. We 
found that expression of both RhoBTB2 and the closely related RhoBTB1 gene 
are required for CXCL14 expression in epithelial cells. Loss of RhoBTB2 expression 
in cancer correlated with loss of CXCL14, and re-expression of RhoBTB2 in cancer 
cells restored CXCL14 expression.
Conclusions  The high incidence of downregulation of RhoBTB2 (ca. 60%) 
and RhoBTB1 (ca. 50%) found across a wide range of carcinomas is suffi   cient 
to explain the observed frequency of downregulation of CXCL14. We propose 
that downregulation of RhoBTB1/2 represents the causative mechanism for 
altered CXCL14 expression in cancer cells. Previous work has shown that CXCL14 
expression is lost from mammary epithelial cells in ductal carcinoma in situ, but 
is upregulated in the surrounding myoepithelial cells. This is suggestive of an 
autocrine to paracrine switch. In keeping with this, we fi  nd that exogenous 
CXCL14 disrupts the organisation of mammary cell acini grown in three-
dimensional culture. Similar switching in CXCL14 production from epithelium 
to stroma has been reported in prostate and oral carcinoma. We are currently 
investigating the contribution of CXCL14 on invasive behaviour.
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Introduction AP-2 transcription factors constitute a family of sequence-specifi  c 
DNA-binding proteins encoded by fi  ve highly homologous yet functionally 
distinct genes, AP-2α to AP-2ε. AP-2γ appears to play a major role in breast 
cancer, being expressed in a large proportion of primary tumours. In this study 
we have analysed in more detail the mechanism of transcriptional regulation 
of the p21/cyclin-dependent kinase inhibitor 1A (p21/CDKN1A) gene by AP-2γ.
Materials and methods Silencing of AP-2γ was carried out in MCF-7 cells using 
siRNA or doxycycline inducible shRNA. Chromatin immunoprecipitation (ChIP) 
assays were performed using specifi  c antibodies against AP-2γ (H77), AP-2α, 
Myc, histone demethylase PLU1/JARID1B, histone H3 and trimethyl dimethyl 
and monomethyl histone H3 followed by quantitative PCR. Electrophoretic 
mobility shift assay (EMSA) competition assay and reporter assays were used to 
identify the AP-2 binding site.
Results Silencing of AP-2γ by either siRNA or inducible shRNA inhibits cell 
proliferation and results in upregulation of p21/CDKN1A expression with no 
induction of apoptosis. ChIP assays demonstrated binding of AP-2γ, PLU1/
JARID1B and Myc to a region adjacent to the transcription start site of the 
p21/CDKN1A gene. Reduction in the binding of cMyc and PLU1/JARID1B and 
increased levels of histone H3 trimethyl-K4 were observed at the proximal 
region of p21/CDKN1A promoter after silencing of AP-2γ. Treatment of MCF-7 
cells with the antimitotic drug vinblastine but not with hydroxyurea reduced 
the CDKN1A binding of AP-2γ, PLU-1/JARID1B and Myc. H3396 cells treated with 
the oestrogen receptor inhibitor Faslodex, which upregulates p21/CDKN1A, 
decreased AP-2γ binding but increased binding of AP-2α at the p21/CDKN1A 
promoter. EMSA competition assays and reporter assays showed that AP-2γ and 
AP-2α bind to a new site (GCC N3 GGG) at position –105 of the p21/CDKN1A 
promoter.
Conclusions The repression of the p21/CDKN1A gene by AP-2γ may contribute 
to the activation of proliferation associated with this transcription factor in 
breast cancer.
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The ability of a tumour to adapt and overcome targeted therapies has been 
recognised clinically for some time, but the molecular mechanisms driving this 
metamorphosis remain unclear. The steroid receptor coactivator protein, SRC-1, 
is a strong predictor of reduced disease-free survival in breast cancer patients. 
SRC-1 can also interact with nonsteroidal transcription factors, and defi  ning 
these new transcriptional networks will uncover fresh strategies for managing 
endocrine resistance.
Here we employed a mass spectrometry-based screen to identify proteins that 
are specifi  c to the endocrine-resistant phenotype. The developmental protein, 
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1. We provide evidence that HOXC11 and SRC-1 cooperate to regulate expression 
of the calcium binding protein S100β in resistant breast cancer cells. Moreover, 
both nuclear HOXC11 and S100β were found to be strong predictors of poor 
disease-free survival in breast cancer patients (n = 560; hazard ratios = 5.79 and 
5.82, respectively; P <0.0001). Elevated serum levels of S100β detected in patients 
also predicted reduced disease-free survival (n = 80; hazard ratio = 5.3; P = 0.004). 
This translational study identifi  es a biomolecular interaction network central to the 
adaptive response to endocrine therapy with clear clinical applications.
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breast cancer cells to chemotherapy
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Introduction  Insulin-like growth factor binding protein-2 (IGFBP-2) is often 
elevated in breast tumours and the presence of IGFBP-2 has been shown to 
correlate with malignancy. Previously we have shown that IGFBP-2 reduces PTEN 
abundance [1] and thus helps to maintain the activity of the phosphoinositide 
3-kinase signalling cascade, a key mitogenic and survival pathway.
Objective We therefore investigated whether IGFBP-2 could act as a survival 
factor for breast cancer cell lines. Using MCF7 and T47D cells, we tested the ability 
of exogenous IGFBP-2 to alter apoptosis induced by various chemotherapeutic 
agents. As both these cell lines produce large amounts of IGFBP-2, we also 
examined the eff  ect of silencing IGFBP-2 using siRNA.
Results In MCF7 cells, paclitaxel (50 μM) increased cell death from 9% to 24.5% 
(P <0.001). Addition of IGFBP-2 (25 ng/ml) decreased the induced cell death 
by almost one-half to 17.7% (P = 0.047). 5-Fluorouricil (20 μM) increased cell 
death of T47D cells by 54% (P = 0.044), which was completely blocked by the 
addition of IGFBP-2. Conversely, loss of IGFBP-2 enhanced chemotherapy-
induced apoptosis in both cell lines compared with a nonsilencing siRNA. We 
also observed that loss of IGFBP-2 reduced cellular proliferation – the live cell 
number decreased 73% (P <0.001) and 33% (P <0.001) in the MCF7 and T47D 
cells, respectively. Additionally, in the MCF7 cells, loss of IGFBP-2 alone increased 
cell death threefold (P <0.001).
Conclusions These data show that the production of IGFBP-2 by breast cancer 
cells enhances their survival and protects them against chemotherapy. Thus 
in breast tumours the increase in IGFBP-2 production could be a survival 
mechanism making IGFBP-2 a legitimate target for intervention.
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Introduction Axillary nodal (LN) stage is the most important prognostic factor 
in early-stage breast cancer (BC) which has risen as a result of widespread BC 
screening. However, surgical procedures for LN staging carry the risk of early 
and long-term postoperative morbidity. Therefore, reliable predictors of nodal 
status are needed to reduce the extent of axillary surgery and its consequences.
Materials and methods Predictive factors of axillary LN status at the time 
of primary diagnosis have been assessed using a broad panel of immuno-
histochemical tissue markers in a well-characterised series (n = 1,130) of primary 
operable (stage I & II) invasive BC cases, temporally divided into training (n = 730) 
and validation (n = 400) sets. Potential predictor factors were initially assessed 
using univariate analysis. A multivariate logistic regression model was fi  tted 
using backward stepwise variable selection in the training set. The resulting 
model was subsequently validated utilising the validation set.
Results Within the training set, the proportion of cancers with positive nodes 
was signifi  cantly higher with younger age, larger tumour size, higher grade, no 
special type tumours, defi  nite vascular invasion (VI), ER-, HER2+, PIK3CA+, and 
high Ki-67 Labelling Index (Ki-67LI). A multivariate logistic regression model 
indicated that predictors of nodal positivity included defi  nite VI, higher grade, 
histological type, tumour size ≥2 cm, HER2+, and Ki-67LI. This model resulted 
in 86.6% accuracy in predicting node positive cases, with area under the curve 
(AUC = 73.1%) and excellent goodness of fi  t (P = 0.981). Model cross-validation 
revealed an AUC of 72.3%.
Conclusions In this study, VI and tumour grade were the strongest independent 
predictive factors of nodal status in BC patients at the time of primary diagnosis. 
Our predictive model, which jointly incorporates VI, tumour grade, histological 
type, tumour size, HER2 status and Ki-67LI, confers an objective predictive 
accuracy relative to single predictive factors.
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Rationale and hypothesis Mutations in high-penetrance genes such as 
BRCA1 and BRCA2 predispose to breast cancer, and recently a number of low-
penetrance breast cancer genes have also been identifi  ed. We reported that a 
coding SNP in the caspase-8 gene (CASP8 D302H) is associated with a reduced 
risk of breast cancer. More recently we identifi  ed a CASP8 4-SNP haplotype 
associated with an increased risk of breast cancer [1]. A CASP8 promoter indel 
has been associated with breast cancer in an Asian population, although this has 
not been confi  rmed in Europeans. Our hypothesis is that these CASP8 variants 
may infl  uence breast cancer susceptibility via eff  ects on the apoptotic response.
Objective Our objectives are to study the functional eff  ects of six relevant 
CASP8 variants on caspase-8 activity and apoptosis induction in peripheral 
blood lymphocytes (PBLs).
Methods We recruited 68 healthy women attending the Sheffi   eld Mammo-
graphy Screening Service and measured the ability of their PBLs to undergo 
drug-induced apoptosis. Levels of apoptosis and caspase-8 activity were 
determined by fl  uorescence-activated cell sorting analysis (Annexin V-FITC with 
PI and Red-IETD-FMK (Calbiochem), respectively). The six SNPs were genotyped 
using TaqMan assays (Applied Biosystems). Data were analysed using parametric 
and nonparametric analysis of variance.
Results The median levels of induction of caspase-8 activity and apoptosis 
were 70.03% (28.19 to 94.65) and 78.11% (18.57 to 92.99), respectively. The rare 
alleles of rs3834129 (promoter indel), rs7608692 (intron 2) and rs1861269 (intron 
4) were associated with reduced caspase-8 activity (P ANOVA = 0.03, 0.005 
and 0.048, respectively). In addition, rs1861269 was signifi   cantly associated 
with reduced apoptosis (P ANOVA = 0.036). Although these results need to be 
confi  rmed, they suggest that SNPs in the caspase-8 gene may infl  uence breast 
cancer susceptibility via eff  ects on caspase-8 activity and apoptosis.
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Introduction Epidemiological studies provide strong evidence of a role for 
endogenous sex hormone levels in the aetiology of breast cancer [1] and 
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hormone levels in premenopausal women, however, is diffi   cult because of their 
cyclical nature. In particular, oestrogen has a marked peak in the follicular phase 
and a further wider peak in the luteal phase.
Methods We developed a protocol to capture peak follicular phase urinary 
oestrone glucuronide (E1G), and luteal phase E1G in healthy premenopausal 
women. Repeated measurements of creatinine-adjusted E1G levels, in 789 
women, were used to describe features of the E1G curve such as mean and 
peak follicular E1G, and luteal E1G. A total of 691 tagging SNPs capturing 
common variation in genes within the oestrogen synthesis and metabolism 
pathways were successfully genotyped. Geometric mean urinary E1G levels 
and endogenous plasma hormone levels were estimated and tested for an 
association with the genotype of each SNP.
Results We identifi  ed a rare SNP (minor allele frequency 7%), in which the minor 
allele was associated with a 20% reduction in circulating levels of E1G in healthy 
premenopausal women (P <10–8). We are currently genotyping this SNP in 
12,000 breast cancer cases and 12,000 controls to test whether the reduction in 
circulating oestrogen levels is also associated with a reduction in breast cancer 
risk.
Conclusions  Circulating hormone levels in premenopausal women may 
provide a useful intermediate phenotype in the search for low-penetrance 
breast cancer risk alleles.
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Objective To evaluate the psychoneuroimmunological eff  ects of refl  exology in 
women with early breast cancer.
Methods One hundred and eighty-three women with early breast cancer were 
randomised 6 weeks post surgery to self-initiated support (SIS) (comparator 
intervention), SIS plus refl  exology, or SIS plus scalp massage (control for physical 
and social contact). Patients randomised to refl  exology and massage had eight 
sessions at weekly intervals. Primary and secondary endpoints were 18 and 24 
weeks post surgery, respectively. Mood, coping and quality of life were assessed 
pre-randomisation, and at the two endpoints. Blood was also taken at these 
three time points to enumerate lymphocyte subsets (CD profi  les), cytokine 
production (Th1, Th2), and hormones (prolactin, cortisol, growth hormone).
Results At week 18, massage, but not refl  exology, was signifi  cantly better than 
SIS in terms of the primary outcome measure, the Trial Outcome Index (TOI) 
of FACT-B. At the secondary endpoint (week 24), refl  exology, but not massage, 
was better than SIS in terms of the TOI. Lymphocyte phenotyping found that 
CD25+ cells were signifi  cantly higher in the massage group compared with the 
SIS group at week 24. The percentage of T cells, more specifi  cally the T-helper 
subset expressing IL-4, decreased signifi  cantly in the massage group compared 
with the SIS group at week 24. An accompanying increase in the percentage 
of CD8+ cytotoxic T cells expressing IFNγ in the massage group showed that 
the immunological balance of patients can be altered in a potentially benefi  cial 
manner by massage. Neither refl   exology nor massage aff   ected any of the 
lymphocyte subsets, or hormones.
Conclusions Refl  exology and massage have modestly benefi  cial eff  ects on 
quality of life. Massage showed statistically signifi  cant eff  ects on immunological 
parameters, although the clinical signifi  cance of these eff  ects will require further 
investigation.
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Tissue banks provide a core facility that enable translational research to be 
undertaken on quality-assured patient-donated samples. These samples 
require clinical and pathological annotations to allow comparisons to be drawn 
between the research-generated data and the conventional pathological and 
clinical outcome parameters. The challenge is to develop a fl  exible database 
system to capture these parameters and to provide a statistical framework for 
automated analysis.
Various database solutions have been developed to capture the data at the 
numerous stages of research. A tissue banking platform allows complete 
tracking of samples as they are frozen, extracted and released, combined with 
an independent pathology database to capture the pathological and clinical 
outcome data for all breast cancer patients. This web-based interface allows 
the appointed research nurse to submit data as they are approved at the Multi 
Disciplinary Team Meetings. The patient records are also routinely checked 
to capture any data relating to disease recurrence, treatments and surgical 
procedures. A digital pathology database is also used to capture and store 
the tissue microarray results. All of these databases are then combined using 
another locally designed system, INSPIRE, which brings all the data together 
to perform statistical analyses and present the results via a user-friendly, web-
based interface.
The various systems developed allow tissue-banked samples to be tracked 
throughout the research process and to be annotated with high-quality 
pathology and research-derived data. INSPIRE then completes the cycle by 
aggregating these data to perform statistical analyses and present these in a 
user-friendly, web-based interface. This allows the researcher to focus purely 
on generating high-quality research and enhancing our knowledge in breast 
cancer.
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Introduction  The problems of adherence to energy restriction in humans 
are well known. Animal data suggest intermittent energy restriction (IER) 
is comparable with or better for preventing breast cancer than continuous 
restriction (CER).
Objective To compare the feasibility and eff  ectiveness of IER with CER for weight 
loss and improving insulin sensitivity and other markers of breast cancer risk.
Methods Randomised comparison of a 25% energy restriction as IER (~2,266 kJ/
day for 2 days/week) and CER (~6,276 kJ/day for 7 days/week) in 107 overweight 
or obese (mean ± SD body mass index = 30.6 ± 5.1 kg/m2) premenopausal 
women over 6 months. Weight, anthropometrics, blood markers for risk of breast 
cancer and other metabolic diseases, insulin resistance, oxidative stress markers, 
leptin, adiponectin, lipids, infl   ammatory markers (high-sensitivity C-reactive 
protein and sialic acid), insulin-like growth factor-I and insulin-like growth 
factor binding proteins, androgens, prolactin and menstrual cycle length were 
assessed at baseline, 1, 3 and 6 months.
Results Eighteen subjects withdrew before 6 months (11 IER, seven CER). Last 
observation carried forward analysis showed IER and CER are equally eff  ective 
for weight loss: mean (95% CI) weight change for IER was –6.4 (–7.9 to –4.8) kg 
vs. –5.6 (–6.9 to –4.4) kg for CER (P for diff  erence between groups = 0.4). Both 
groups had signifi  cant and comparable improvements in disease risk markers; 
however, IER was signifi  cantly better than CER in reducing insulin resistance: 
mean (95% CI) change for IER was –28 (–37 to –17)% vs. –15 (–24 to –4)% for CER.
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Its additional benefi  cial eff  ect on insulin sensitivity indicates that it may be an 
alternative approach for weight loss.
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Redox systems are often deregulated in cancer. To investigate whether 
altered expression predicted response to therapy, core biopsies from 80 
locally advanced breast tumours (pre-six cycles of fl  uorouracil epidoxorubicin 
cyclophosphamide/fl  uorouracil adriamycin cyclophosphamide chemotherapy) 
were stained, using standard immunohistochemistry, to examine members of 
the Trx system (Trx1, TrxR and TxNIP), GST-π, GST-θ, catalase and MnSOD, and 
results were correlated with clinicopathological criteria. Signifi  cant results were 
obtained between TxNIP and progression-free survival (P = 0.008) and overall 
survival (P = 0.05), with low expression predicting a worse prognosis. A redox 
protein profi  le was developed, using an artifi  cial neural network approach, with 
four of the proteins (catalase, GST-θ, GST-π and TxNIP), that stratifi  es patients into 
good/poor prognostic groups for overall survival with an 88% sensitivity and 
87% specifi  city.
Conventional  in vitro studies show that, using MCF-7 cells, targeting the 
Trx system by pretreatment with novel inhibitors (PMX464, PMX290 or IV-2) 
sensitises resistant cells to conventional C/T but that sensitivity of the parental 
line remains unchanged. Initial results, using single agents in novel three-
dimensional (3D) systems, shows diff  erential chemosensitivity, between normal 
and malignant cells, that is not apparent using conventional two-dimensional 
(2D) systems. Parental cell lines (MCF-7, MDA-MB-231) maintain or become more 
sensitive when exposed in 3D to conventional chemotherapy and Trx inhibitors 
(doxorubicin, PMX464/PMX290, IV-2 that is IC50 2D and 3D 0.01 μM, 0.5 μM, 25 μM 
– paclitaxel IC50 3D <0.01 μM, 2D 0.01 μM), assessed by clonogenic survival. 
Normal breast epithelial cells (MCF10As), however, show increased resistance 
to drugs (paclitaxel, doxorubicin, PMX464/PMX290, IV-2 IC50 3D 0.1 μM, 1 μM, 
>10 μM, 200 μM – IC50 2D 0.05 μM, 0.01 μM, 0.5 μM, 25 μM, respectively). The 
reasons for such altered chemosensitivity in 3D matrices are a focus of current 
work.
Results from the immunohistochemistry and in vitro studies suggest the 
suitability of targeting redox proteins, particularly the Trx system, in breast 
cancer to improve the effi   cacy of conventional therapies.
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There is increasing evidence that recurrent metastatic breast cancer arises in 
part due to the presence of long-lived, slow-cycling, and drug-resistant stem 
cells. Adult stem cells, known as side population (SP) cells, whose phenotype 
has been demonstrated to be due to the expression of ABCG2, are known to be 
resistant to a number of structurally unrelated compounds. In the present study 
we have observed that while both oestrogen-responsive and non-oestrogen-
responsive breast cancer cell lines contain SP, exhibit multidrug resistance 
and express elevated levels of ABCG2, the non-oestrogen-responsive more 
highly metastatic MDA-MB-231 SP cells exhibit higher levels of mitoxantrone 
resistance than the other cell populations examined. These SP cells would 
therefore have a higher survival capacity when exposed to many currently 
utilised therapeutic regimes. Importantly, we have shown there is a statistically 
signifi  cant relationship between the presence of these SP cells in fi  ne needle 
aspirates associated with ER-negative palpable breast lesions, and that these 
cells are more frequently associated with triple-negative breast tumours. Novel 
treatments directed against SP cells should be sought to off  er patients better 
treatment strategies in these triple-negative tumours that fail to respond to 
conventional targeted therapy. Further analysis of this small population of 
potentially important cells is warranted.
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Objective To develop a sensitive and specifi  c pathology-based predictor to 
improve identifi  cation of BRCA1 and BRCA2 gene carriers.
Methods We assembled a training panel of breast cancer tumour blocks from 
67 BRCA1, 71 BRCA2 associated and 105 sporadic young onset cases (≤40 years 
at diagnosis) from the Prospective study of Outcomes in Sporadic versus 
Hereditary breast cancer (POSH) study. Gene carriers were matched to sporadic 
cases for ER status. Tissue microarrays were assembled and subjected to 
immuno  histochemical analysis with a panel of 18 antibodies. DNA from tumour 
tissue and matched patient lymphocytes was subjected to high-resolution 
tiling path microarray-based comparative genomic hybridisation (aCGH). Bio-
informatics analysis highlighted DNA regions signifi   cantly diff  erentially  lost, 
gained or amplifi  ed in BRCA1 or BRCA2 carrier tumours compared with controls. 
Chromogenic in situ hybridisation (CISH) identifi  ed amplifi  cations in all training 
samples.
Results Two neighbouring regions of diff  erential amplifi  cation (3q25.31 and 
3q25.2) were identifi  ed in BRCA1 cases and one in BRCA2 cases (20q13.13). As 
expected, ER, PR and HER2 negative status was highly predictive of a BRCA1 
gene carrier. Using just ER and HER2 plus the CISH probes we were able to 
assign BRCA1 and BRCA2 cases accurately in 74% and 81% of cases tested. The 
probability of misclassifying a control as a carrier was 5% and 12% in each case. 
These results equated to positive and negative predictive values of 0.92 and 0.90 
for BRCA1 and 0.72 and 0.92 for BRCA2. The BRCA1 and BRCA2 tumour tests are 
being validated in a new set of tissue microarrays comprising 223 tumours from 
the POSH study.
Conclusions This tumour-based predictor for BRCA1 and BRCA2 carriers may 
prove useful to identify gene carriers at low a priori chance of having a mutation, 
to direct BRCA1/2 targeted treatment approaches and to identify familial non-
BRCA1/2 cases that may be suitable for new gene discovery studies.
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Melanoma-associated antigen (MAGE) family genes are broadly expressed 
during development and are involved in the regulation of cell survival, cell 
cycle progression and apoptosis. MAGE family proteins are generally described 
as tumour-specifi   c antigens and as representing ideal targets for cancer 
immunotherapy. In the current study, we identifi   ed melanoma-associated 
antigen protein-D4 (MAGE-D4), a recently characterised MAGE family member, 
as a new prognostic biomarker and potential therapeutic target for breast cancer. 
Specifi  cally, in a whole genome microarray analysis of 103 cases of invasive 
breast tumours, MAGE-D4 expression was observed in 43.8% of tumours, while 
undetectable in normal breast tissue. Multivariate and univariate analyses also 
indicated MAGE-D4 expression to be associated with tumour grade, spread 
to lymph nodes and shortened times to relapse (P = 0.0369) and death (P = 
0.0133) from time of cancer diagnosis; suggesting a role for MAGE-D4 in tumour 
progression. To further investigate the involvement of MAGE-D4 in breast cancer 
cell biology, the phenotypic eff  ects of this gene were characterised in vitro. We 
observed a marked upregulation of MAGE-D4 expression – at both mRNA 
and protein levels – in the breast cancer cell line Hs578T compared with the 
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knockdown of MAGE-D4 expression in Hs578T cells signifi  cantly reduced cell 
migration and invasion and correlated with inhibition of STAT3 and NF-κB p65 
subunit phosphorylation, thus aff   ecting two common signalling pathways 
involved in regulating cancer progression. Moreover, monolayer cell growth 
rate was not aff  ected by MAGE-D4 gene knockdown, while growth in soft agar 
was signifi  cant compromised. Our results indicate that MAGE-D4 contributes to 
the tumorigenesis of breast cancer cells by regulating migration, invasion and 
anchorage-independent growth, and therefore may represent a novel target for 
the detection and treatment of breast cancer.
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Breast cancer is not a single disease but is highly heterogeneous at both the 
molecular and clinical levels. Gene expression profi   ling of breast tumours 
by multiple independent groups and technologies have revealed fi  ve major 
molecular subtypes of breast cancer. These molecular diff   erences result in 
distinct clinical outcomes and responses to treatment.
The gene expression profi   ling studies that have defi   ned the molecular 
subgroups of breast cancer to date were performed using fresh frozen tissue. 
Routine clinical practice dictates the preservation of surgical specimens via 
paraffi   n embedding of formalin-fi  xed tissue. Therefore, derivation of molecular 
subgroups of breast cancer from formalin-fi   xed, paraffi   n-embedded  (FFPE) 
preserved tissue would have more application in the clinical setting as such 
profi  les could be applied to routinely collected specimens.
The Almac Diagnostics’ Breast Cancer DSA™ has been optimised for analysis 
of FFPE samples enabling the use of these valuable archived tissue banks. We 
have demonstrated the ability to identify the molecular subgroups previously 
defi  ned within a cohort of sporadic, BRCA1 mutant and BRCA2 mutant FFPE 
breast tumours as well as defi  ning two novel subgroups within this tumour set.
This study demonstrates that it is possible to derive biologically meaningful data 
from a cohort of archived FFPE tumour samples using the Almac Breast DSA™. 
We demonstrate that there is considerable molecular diversity within BRCA 
mutant and sporadic breast tumours, suggesting that traditional assumptions of 
the behaviour of tumours based on their immunohistochemistry status may not 
always be correct. At present, a number of clinical trials are stratifying patients 
for poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor therapy based on BRCA 
mutation and triple-negative status. The data presented here would suggest 
that not all BRCA1 mutant, BRCA2 mutant and indeed triple-negative patients 
are similar at the molecular level and as such will not respond equally to PARP-1 
inhibitor or indeed other therapeutics in the same manner.
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The study of gene expression in conventionally processed tissues is hampered 
by degradation of mRNA. Expensive, low-multiplex, quantitative PCR methods 
can be unreliable due to the limited template sizes. One way to overcome this 
problem is to use array-based methods. DASL® technology relies on random 
priming for production of cDNA, in concert with universal bead arrays to allow 
the detection and relative quantitation of expression of specifi  c gene subsets.
Using the Illumina DASL® Cancer Panel (500 cancer-associated genes on one 
array), we evaluated the expression of key genes in archival formalin-fi  xed, 
paraffi   n-embedded tissue samples from 80 breast cancer patients with well-
characterised pathological and clinical features. We fi   rst assessed transcript 
integrity in the samples on the basis of levels of mRNA encoding RPL13A, prior 
to running the Cancer Panel. A subset of genes of interest was then assessed by 
quantitative PCR to confi  rm the relative levels observed using the DASL® assay. 
Finally the expression of the same subset of genes was evaluated at the protein 
level by immunohistochemistry.
We were able to predict, with good accuracy based upon RPL13A  assays, 
those samples unsuitable for DASL® analysis. Furthermore, the results of 
DASL® analysis showed good correlation with protein levels, as measured by 
immunohistochemistry, for a number of key genes including ERBB2 (HER2) and 
ESR1 (ER). We conclude that DASL® represents a powerful tool for assessing 
expression of multiple genes in archival tissue.
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Paclitaxel is a microtubule inhibitory chemotherapeutic drug that is increasingly 
used for the treatment of solid tumours. In vitro studies have demonstrated 
that attenuating the spindle assemble checkpoint (SAC) alters the post-mitotic 
responses to paclitaxel. Furthermore, the aberrant expression of a number of 
the SAC proteins, MAD2, BUBR1, and Aurora A kinase, are associated with poor 
patient prognosis. We have identifi   ed a microRNA, miR-433, that regulates 
the expression of MAD2. Overexpression of miR-433 in Hela cells induced 
downregulation of MAD2 mRNA and protein expression. We have also shown 
that Hela cells overexpressing miR-433 and treated with paclitaxel are no longer 
capable of cyclin B stabilisation, and thus have lost the ability to activate the 
SAC in response to paclitaxel. In addition, cell viability assays showed that Hela 
cells overexpressing miR-433 and treated with paclitaxel have an attenuated 
response to paclitaxel compared with microRNA scrambled controls. We have 
characterised the levels of miR-433, MAD2 gene expression and MAD2 protein 
levels in a cohort of ovarian cancer cell lines. Cell viability assays on this cohort 
revealed that responsiveness to paclitaxel is associated with high MAD2 protein 
expression and lower miR-433 expression. We hypothesise that the expression 
of miR-433 when deregulated in cancer leads to altered MAD2 expression and 
a compromised SAC, a key feature underlying drug resistance to paclitaxel. In a 
pilot study of paired human breast tumour and normal breast tissue samples 
we have shown that expression levels of miR-433 are elevated in cancer tissue. 
Targeting this microRNA in cancer may improve the effi   cacy of paclitaxel in 
treating breast cancer and ovarian cancer.
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Introduction  There is currently extensive diagnostic use of breast tissue 
calcifi  cations through their diff  erential mammographic appearance, albeit with 
relatively low specifi  city. However, the details of the calcifi  cation chemical and 
structural composition remain somewhat vague. Thus any associated clinical 
signifi  cance, such as indications of tumour type, grade and stage, have not 
previously been explored.
Methods The biochemical composition and incorporation of carbonate into 
the hydroxyapatite lattice of type II microcalcifi  cations was studied by infrared 
microspectroscopy, allowing spectral information to be directly correlated with 
associated histopathology of the surrounding tissue.
Results It was shown that the chemical characteristics of calcifi  cations asso  ciated 
with benign, in situ and invasive pathologies are signifi  cantly diff  erent. For the fi  rst 
time, a relationship between grade of pathological breast disease and chemical 
nature of associated microcalcifi  cations has been demonstrated. In particular 
we have found signifi  cant correlations between distinct pathology grades and 
physiochemical features such as the carbonate content of micro  calcifi  cations and 
protein to mineral ratios. Further, such correlations were also demonstrated within 
carcinoma in situ and invasive cancer subgrades. Quantifi  cation of the calcifi  cation 
carbonate content indicated that the degree of carbonate substitution followed 
a monotonic trend between benign, ductal carcinoma in situ (DCIS) and invasive 
pathologies (see Figure 1). This suggests that benign tissue calcifi  cation (consisting 
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DCIS, which in turn will result in invasive disease.
Conclusions This study a greater signifi  cance for microcalcifi  cation chemistry 
in mechanisms associated with cancer progression, and especially for the future 
diagnosis and classifi  cation of breast pathology.
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Introduction Migration stimulating factor (MSF) is a novel angiogenic factor 
previously identifi  ed in breast tumours and their associated stroma. The aim of 
this study was to determine the possible diagnostic and prognostic value of 
MSF expression in these tumours and its eff  ects on breast-derived cells in vitro.
Methods Paraffi   n-embedded archival breast tissues were stained with specifi  c 
MSF antibodies and the level of staining was semiquantifi  ed either by consensus 
of two or three independent observers or by computer-assisted image analysis. 
The eff  ects of rhMSF on the migration and proliferation of breast carcinoma 
cells, fi  broblasts and endothelial cells were examined in tissue culture.
Results MSF expression was generally low or negligible in normal breast tissue 
derived from reduction mammoplasties (NB; n = 19). However, histologically 
normal breast from the resection margin of breast tumours (NB-T; n = 17) 
showed signifi  cantly higher expression than NB. Signifi  cant increases in MSF 
expression were also observed from NB to benign lesions (B; n = 8) and from any 
of these tissues (B, NB or NB-T) to malignant tumours (T; n = 23), whereas B and 
NB-T showed similar expression.
MSF was detected in approximately 85% of the tumours examined, being 
heterogeneously expressed in carcinoma cells as well as in fi  broblasts and blood 
vessels. In a cohort of 71 tumours, high MSF expression was associated with 
larger tumour size and shorter patient overall survival. Stromal MSF produced 
the most signifi  cant results. Recombinant MSF stimulated the migration, but not 
the proliferation, of breast carcinoma cells, fi  broblast and endothelial cells.
Conclusions This study indicates that MSF expression is associated with breast 
tumour development and aggressiveness. Besides inducing angiogenesis, MSF 
acts as an autocrine and paracrine motogen in breast tissues.
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Introduction The existence of breast cancer-initiating cells was initially demon-
strated by Al-Hajj and colleagues [1] using antigen expression, and subsequent 
studies have employed several methodologies to identify and isolate these cells. 
However, there are limited data describing whether similar cell populations are 
recognized by the diff  erent approaches.
Materials and methods Using breast cancer cell lines MCF7, MDAMB231 
and MDAMB468, we have compared the antigen expression profi   le 
(CD44+CD24−/low) against the side population and the ability to form tumour 
spheroids. Immunostaining on cells and xenografts was also performed to 
search for expression of potential stem cell markers.
Results Our data showed increased CD44+CD24−/low population in both MCF7 
and MDAMB468 spheroids, but growth advantage was only observed in sorted 
MDAMB468 CD44+CD24−/low cells. In contrast, analysis of the antigen profi   le 
of the side population did not demonstrate any correlation and no growth 
advantage was found in sorted MCF7 and MDAMB468 cells. Immunostaining 
of MCF7-derived tumour xenografts showed two potential markers, p63 and 
sox2, in addition to CD44; both MDAMB231 and 468-derived xenograft expressed 
strong CD44, and the latter was also stained for p63 and aldehyde dehydrogenase 
(ALDH). In addition, comparison between the antibodies only demonstrated 
partial overlap between CD44 and p63/ALDH in MCF7 and MDAMB468 
xenografts. Therefore, in MCF7/MDAMB468-like breast tumours, p63 and sox2/
ALDH recognize diff  erent stem/progenitor cell populations, and the combination 
of CD44 and p63/ALDH further clarifi  es the boundary of these cells.
Conclusions  Our results indicate that each breast cancer is unique, and 
therefore tumour-initiating cell markers and methodologies should be applied 
specifi  cally.
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Introduction Dysfunctional mitochondria contribute to the onset of malignant 
transformation and growth. Molecules that regulate mitochondrial homeostasis 
are therefore the object of great attention to identify novel therapeutic 
strategies. The mitochondrial translocator protein (mTSPO) stands in a critical 
position for mitochondrial homeostasis and is involved in the physiology 
of breast cancer where it is overexpressed and positively associated with 
aggressiveness [1]. mTSPO ligands are therefore exploited for cancer imaging 
and chemotherapy, such as PK11195. mTSPO is associated with the voltage-
dependent anion channels (VDACs), which regulate the metabolites’ fl  ux into 
mitochondria [2]. mTSPO expression is driven by the oncogene protein kinase 
Cε, suggesting a fundamental crosstalk for malignant transformation and 
uncontrolled proliferation. We hypothesized that mTSPO by regulating VDAC 
performance impinges on metabolism and pharmacologically induced cell 
death in breast cancer cells.
Results In human breast adenocarcinoma MCF-7 and in cervical cancer cells 
(HeLa) we found, via imaging and luminescent-based approaches, that a decreased 
mTSPO/VDAC ratio of expression uperegulates mitochondrial Ca2+ uptake and 
ATP generation whilst reducing the rate of reactive oxygen species generation 
calling for a metabolic switch via an improvement of mitochondrial function. 
mTSPO suppression also impairs protein kinase Cε activation and facilitates Ca2+-
dependent apoptosis triggered by C2-ceramide. Nevertheless, mTSPO targeting 
with PK11195 – which impinges on Ca2+ homeostasis [3] – raises C2-ceramide cell 
death in MCF-7 and in the more aggressive line of adenocarcinoma MDA10 – 
characterized by an increased mTSPO/VDAC ratio of expression.
Figure 1 (abstract P36). Apatite %CO3
2– for each pathology group.
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signalling of breast cancer and paves the way for future studies to exploit mTSPO 
as a suitable prognostic marker and target for molecular chemotherapy.
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Introduction A signifi  cant proportion of patients presenting with large locally 
advanced breast tumours, treated with neoadjuvant chemotherapy (NAC), show 
a poor or partial response to the treatment. The aim of this study is to identify 
novel phospho-proteins that may predict responsiveness to NAC treatment as 
there are no such biological markers available in the clinic to date.
Materials and methods Frozen tissues collected before (core biopsies) and after 
NAC (surgical tissues) were categorised by pathological response (complete 
response, no response and progressive disease). Lysates were enriched for 
tyrosine phospho (pY) proteins and separated in two dimensions by IEF and 
PAGE. Proteins showing consistent diff   erences in tyrosine phosphorylation 
from the diff   erent response groups were identifi   ed by mass spectrometry 
(MALDI-TOF) and using the NCBInr sequence database (ProFound). Functional 
and pathway analysis was performed using Ingenuity Pathway Analysis (www.
ingenuity.com).
Results Phospho-protein expression profi  les were successfully established from 
core biopsies and surgical tissues. Proteins involved in cell division, polarisation 
and microtubule formation such as PAR6D and Kif3 were identifi  ed in core 
biopsies from the complete response group. In the no response/progressive 
disease group, proteins such as CHIMP, ZAP70, and serologically defi  ned breast 
cancer antigen (NY-BR-15) were distinguished. Further network pathway analysis 
in this disease group suggested that two main signalling pathways, TP53 and 
TNF, may be involved in NAC nonresponsiveness.
Conclusions  Proteins and pathways were identifi   ed that showed scientifi   c 
and clinical relevance to NAC responsiveness. Our data support the largely 
confl  icting evidence that suggests P53 and TNF may be possible predictive 
markers for NAC responsiveness. These fi   ndings may lead to the accurate 
prediction of chemotherapy responsiveness in breast cancer patients and to the 
development of personalised treatment plans for future patients.
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Introduction Previously we identifi  ed MCPH1, a DNA damage response protein 
involved in the regulation of BRCA1 and BRCA2, as the defective protein in one 
form of microcephaly. BRCA1 mutations are associated with basal-like breast 
cancer, which are often also negative for oestrogen receptor (ER), progesterone 
receptor (PR) and HER2. Our data indicate that MCPH1 plays a role in response to 
chemotherapeutic agents used in the treatment of breast cancer due to its role 
in DNA repair and the spindle checkpoint.
Methods MCPH1 immunohistochemistry was performed on 320 breast cancers 
and correlated with pathology, survival, ER, PR and HER2 data. Drug assays were 
performed on the breast cell lines MCF10A, MCF7 and HCC193 with diff  erent 
MCPH1 and BRCA1 backgrounds created using siRNA.
Results We identifi  ed reduced MCPH1 expression in 23% (74/320) of breast 
cancers. After performing continuous data analysis, the mean MCPH1 expression 
decreased with increasing grade, grade 1 and 2 versus grade 3 (P <0.006). 
Interestingly, mean MCPH1 expression was also lower in ER/PR-negative 
(P <0.001) and triple-negative cancers (P <0.004). An association with HER2-
positive cancers was also identifi  ed (P <0.03). While no association with survival 
was identifi  ed initially, the longer term survival was better in patients with 
higher mean MCPH1 expression. Our cell line drug assays indicate that MCPH1 
plays a role in resistance to Taxol and sensitivity to cisplatin and doxorubicin.
Conclusions MCPH1 expression is reduced in 23% of breast cancers, particularly 
in higher grade tumours. Interestingly, reduced mean MCPH1 expression was 
associated with the triple-negative phenotype often seen in basal-like cancers. 
Further basal cell markers are currently under investigation. Aggressive basal-
like breast cancers have a poor prognosis; MCPH1 expression may potentially 
improve treatment of these cancers.
Acknowledgements This work was supported by Breast Cancer Campaign and 
Yorkshire Cancer Research.
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Introduction  Overexpression of human epidermal growth factor receptor 
2 (HER2) tyrosine kinase cell surface receptor occurs in 25 to 30% of all breast 
cancer and is linked to aggressive phenotype and high-mortality disease. HER2 
is a clinically important target in diagnosis and treatment of breast cancer but 
despite its pivotal role there are no established tools for quantitative clinical 
imaging of the extent and location of HER2-positive (HER2+) tumours in 
patients. Such a tool could provide important clinical diagnostic information by 
early detection of subclinical HER2+ disease, optimal management of current 
anti-HER2 therapies and response assessment of novel therapeutics. We aimed 
to generate recombinant proteins that would achieve sensitive and specifi  c 
detection of HER2+ tumours in the clinic using radioimmunoimaging.
Materials and methods Two diff  erent HER2-binding molecules were investi-
gated: C6.5 a small dimeric antibody fragment (diabody), which is approximately 
1/3 of the size of an antibody; and G3, a small monomeric designed ankyrin 
repeat protein (DARPin) that is 1/10 the size of an antibody. The agents were 
generated in the yeast Pichia pastoris system using processes compliant with 
good manufacturing practice (GMP). C6.5 and G3 production strains were 
constructed to allow methanol-inducible, soluble expression. The expressed 
proteins were purifi   ed using expanded-bed adsorption–immobilized metal 
affi   nity chromatography.
Results and conclusions For C6.5 the fi  nal product was homogeneous, stable 
and free of host cell and other relevant contaminants. The protein was stable 
during storage, with no evidence of aggregation. In addition, affi   nity for HER2, 
as measured by Biacore analysis, was not compromised by storage at either 4 or 
–80°C. Preliminary results with the G3 DARPin indicate that this protein is also 
amenable to GMP production in P. pastoris. The relative effi   cacy of these agents 
for specifi  c radioimmunoimaging of HER2+ tumours in vivo is currently under 
investigation.
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Introduction Global expression profi  ling by microarray can provide invaluable 
information about biological properties of breast cancers. Here I report 
predicted gene regulatory networks of known breast cancer risk genes using 
multiple microarray data, in order to understand how the risk genes interact 
with each other and how the interaction may be related to the pathogenesis 
of breast cancer.
Methods I used microarray data of breast cancer samples from four published 
studies. By combining the data from three smaller studies, I obtained two 
datasets with 548 and 684 samples, respectively. For each dataset, Pearson 
coeffi   cients of expression levels between 74 known breast cancer risk genes 
were calculated fi  rst. The gene association network was also obtained by a 
new correlation metric called asymmetric correlation, which quantifi   es the 
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combined to obtain predicted gene regulatory networks.
Results  I found in both datasets that ESR1, GATA3 and FOXA1 formed a 
close cluster and each of them had interactions with a number of genes. In 
particular, FOXA1 showed positive interactions with ERBB2 and IGF1R while 
ESR1 and GATA3 were positively associated with NAT2 in both datasets. Positive 
associations were also found between AGTR1, FOXA1 and GATA3, and between 
CDH1, NAT2 and FGFR2. Moreover, FGFR2 and AGTR1 had negative associations 
with ERBB2, indicating that they have overwrapping but distinct gene network.
Conclusions Transcription factors ESR1, GATA3 and FOXA1 were found to form 
a core network, which was connected by plasma membrane signal transducers 
ERBB2, IGF1R and AGTR1. FGFR2 and CDH1 are associated with this network, but 
they seem to play distinct roles in breast cancers.
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Introduction The BRCA1 tumour suppressor gene is mutated in a signifi  cant 
proportion of hereditary breast cancer cases. Downregulation of BRCA1 mRNA 
and protein expression has also been reported in approximately 30% of sporadic 
breast cancer cases. BRCA1 is strongly implicated in the maintenance of genomic 
stability by its involvement in multiple cellular pathways including DNA damage 
signalling, DNA repair, cell cycle regulation, protein ubiquitination, chromatin 
remodelling, transcriptional regulation and apoptosis. Both pathological and gene 
expression profi  ling studies provide evidence that breast cancers with germline 
mutations in BRCA1 are diff  erent from non-BRCA1-related breast cancers.
Methods  Extensive gene expression profi   ling and data analysis has been 
performed on a cohort of 70 formalin-fi  xed, paraffi   n-embedded-derived BRCA1 
mutated breast tumours and matched sporadic controls using the Almac Breast 
Cancer DSA™ research tool. Validation of gene targets has been performed by 
quantitative RT-PCR and western blotting.
Results  A list of diff  erentially expressed transcripts has been derived from 
the comparison of these BRCA1 mutant breast tumours to matched sporadic 
controls. Functional analysis of this gene list was performed to identify the 
main pathways and processes that are deregulated by these transcripts. BRCA1 
defi  ciency was associated with deregulation of pathways involved in: immune 
response, metastasis and invasion, cytoskeletal remodelling, spindle assembly 
and chromosome separation, and apoptosis and survival. We have now 
validated several panels of genes that characterise this BRCA1-defi  cient breast 
cancer profi   le. A high-throughput siRNA-based screening strategy will now 
be performed to identify functionally relevant BRCA1-associated gene targets 
involved in cell growth, diff  erentiation and chemotherapy response.
Conclusions This approach has identifi  ed a set of transcripts that could be used 
to identify both hereditary and sporadic breast cancer patients with BRCA1 
defi  ciency.
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Approximately 40% of patients with oestrogen receptor (ER)-positive breast 
cancers do not respond to endocrine therapies; furthermore, most responsive 
tumours eventually become resistant. We have identifi  ed a novel oestrogen-
responsive Hsp90 co-chaperone and immunophilin, FKBPL, which aff  ects the 
stability and signalling of ER with implications for breast cancer growth and 
sensitivity to endocrine therapies. MCF7 cells stably overexpressing FKBPL 
demonstrate a slower rate of proliferation and become highly dependent on 
oestrogen for their growth. This dependence on oestrogen renders these cells 
dramatically more sensitive to tamoxifen and fulvestrant. FKBPL overexpressing 
cells also exhibit decreased levels of ER and an oestrogen-responsive gene, 
cathepsin D, critical for breast cancer growth, survival and invasion. Moreover, 
knockdown of FKBPL using a targeted siRNA approach dramatically increases 
both ER and cathepsin D protein levels and cell resistance to tamoxifen. FKBPL has 
been previously implicated in the stabilisation of the cyclin-dependent kinase 
inhibitor, p21 [1]. Loss of p21 has been associated with a tamoxifen growth-
inducing phenotype and hyperphosphorylation of ER at Ser118, with increased 
expression of ER-regulated genes. Following FKBPL knockdown, we have 
observed a fall in p21 levels and subsequent increase in Ser118 phosphorylation 
following treatment with 17β-estradiol or tamoxifen while FKBPL overexpressing 
cells exhibit the reverse eff  ects. Our in vitro data support a model in which high 
levels of FKBPL would stabilise p21, decrease ER phosphorylation and abrogate 
tamoxifen-induced agonist potency, thereby increasing drug sensitivity, and 
suggest that FKBPL may have prognostic value that might impact upon tumour 
proliferative capacity and improve patient outcome. In addition, analysis of two 
publically available breast cancer microarray patient cohorts demonstrated 
that high FKBPL expression was correlated with increased overall and distant 
metastasis-free survival.
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Introduction  Tamoxifen has an established role as the standard adjuvant 
therapy for early oestrogen-receptor-positive breast cancer. Aromatase inhibitors 
are now licensed for adjuvant treatment following 2 to 3 years of tamoxifen. This 
switch therapy off  ers both disease-free and modest overall survival advantages 
compared with 5 years of tamoxifen [1]. Greater Midlands Cancer Network 
guidelines based on NICE guidelines (2006) recommend switch therapy in 
patients who are not at low risk of recurrence [2]. There are no reports in the 
literature to indicate whether this is currently happening in clinical practice. We 
examined our own patient population to see if high-risk patients were being 
switched appropriately.
Methods  Retrospective audit of all females diagnosed with invasive breast 
carcinoma between July 2006 and December 2007 at the University Hospital 
of North Staff  ordshire.
Results Of the 291 women diagnosed with invasive breast cancer, 13 fulfi  lled 
the inclusion criteria. Forty-six per cent of these were switched appropriately. In 
the remaining 54% of cases a switch had not been considered.
Conclusions More than one-half of the women receiving adjuvant tamoxifen 
are not being considered for a switch, which puts them at an increased risk of 
disease recurrence. Factors identifi  ed by the audit that could be modifi  ed to 
improve practice are: highlighting the tamoxifen start date in the patient notes 
to enable the reviewing clinician to more easily identify when a switch is due, 
and clearer ownership of ongoing adjuvant therapy between surgeons and 
oncologists.
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Introduction Anthracyclines play an important role in the treatment of breast 
cancer but their benefi  cial therapeutic eff  ects may not be the same for all 
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biomarkers of response could be identifi  ed. Topoisomerase 2 alpha (Topo2α) is a 
target of anthracyclines and has been proposed as a chemosensitivity marker of 
anthracycline-containing therapies by in vitro and in vivo studies. But the method 
to detect it remains a controversial issue. Treatment in the neoadjvant setting is a 
unique opportunity to examine biomarkers of response to chemotherapy.
Objective  To examine the role of Topo2α in response to anthracycline 
neoadjuvant chemotherapy both at the protein level by immunohistochemistry 
(IHC) and at the gene level using chromogen in situ hybridisation (CISH).
Patients and methods This study includes 100 locally advanced breast 
cancer  patients treated by fl   uorouracil, epirubicin, and cyclophosphamide 
(FEC) chemotherapy from 1999 to 2008. Pretreatment core biopsy is used to 
study diff  erent biologic markers (basal cytokeratin, EGFR, Ki-67, p53, and Her2) 
including Topo2α by IHC and to correlate the expression level with the rate of 
pathological complete response (pCR). CISH is used to determine the level of 
Topo2α gene amplifi  cation.
Results In the initial analysis of the fi  rst 64 patients, the rate of clinical complete 
response (CR) and pCR were 40.6% and 19.7%, respectively. Prechemotherapy 
Topo2α protein expression correlated with both clinical CR (P = 0.006) and pCR 
(P = 0.001). On multivariate analysis, only Topo2α expression correlated with 
pCR (P = 0.03). A correlation between Topo2α protein expression and gene 
amplifi  cation will be made.
Conclusions The study demonstrates the importance of Topo2α as a predictor for 
both clinical CR and pCR to neoadjuvant anthracyclines in locally advanced breast 
cancer. Furthermore, it could be considered as part of pretreatment evaluation to 
help in improving the selection of patients for this type of treatment.
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Introduction Tamoxifen effi   cacy may be infl  uenced by a number of factors, 
including CYP2D6 genotype, co-administration of drugs that inhibit CYP2D6, 
and adherence to tamoxifen therapy. CYP2D6 plays a major role in catalyzing 
the conversion of tamoxifen to its active metabolite endoxifen. Studies of the 
relevance of CYP2D6 genotyping have had confl  icting results due to various 
limitations: diff  erences in CYP2D6 allele coverage, phenotype classifi  cation and 
other confounding variables.
Methods Using archival samples from two UK cohorts of tamoxifen-treated 
women with invasive breast cancer (Dundee, n = 391; Manchester, n = 227), 
we estimated the association of inferred CYP2D6 metabolic phenotypes with 
recurrence-free survival time (RFS) using Cox proportional hazard models, 
adjusted for nodal status and tumor size. Comprehensive CYP2D6 genotyping 
was performed using the AmpliChip CYP450 test.
Results Sixty percent of patients had at least one reduced-function CYP2D6 
allele and 6% had no functional alleles. Analysis of the entire group revealed a 
nonsignifi  cant trend for worse RFS in patients with any reduced function alleles 
– HR = 1.52 (CI = 0.98 to 2.36, P = 0.06). In the subset of postmenopausal women 
on tamoxifen monotherapy, the HR for recurrence for patients with reduced 
functional alleles was 1.96 (CI = 1.05 to 3.66, P = 0.036). When the analysis was 
limited to four common allelic variants of CYP2D6 [1], this diff  erence was not 
apparent.
Conclusions This study indicates that patients with two fully functional CYP2D6 
alleles are more likely to experience the full therapeutic benefi  t of tamoxifen. 
The apparent adverse eff  ect of reduced function alleles is best detected by a 
genotyping test with comprehensive CYP2D6 allele coverage that captures 
uncommon variants with decreased function.
Reference
1.  Schroth W, Antoniadou L, Fritz P, et al.: Breast cancer treatment outcome 
with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 
genotypes. J Clin Oncol 2007, 25:5187-5193.
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Insulin-like growth factor receptor (IGF-IR) signalling classically involves 
phos  phory  lation of insulin receptor substrate-1 (IRS-1) to recruit key down-
stream signalling pathways eff   ecting breast cancer cell proliferation and 
survival. Recently, we have shown a further capacity for IRS-1 to associate 
with the epidermal growth factor receptor (EGFR/erbB1), with activation of 
EGFR promoting recruitment and phosphorylation of IRS-1 in an oestrogen 
receptor (ER)-positive tamoxifen-resistant breast cancer cell line. In this study, 
we examined recruitment of IRS-1 by another member of the erbB receptor 
family, erbB3, in three ER-positive breast cancer cell lines. Our studies revealed 
an interaction between erbB3 and IRS-1 in MCF-7, T47D and BT474 cells with 
HRGβ1 treatment signifi  cantly enhancing this recruitment and promoting IRS-1 
phosphorylation at tyrosine (Y) 612, a specifi  c phosphoinositide 3-kinase (PI3K) 
binding site. IRS-1 appears to play a key role in erbB3 signalling in MCF-7 and 
T47D cells as its knockdown using siRNA greatly impaired HRGβ1 signalling via 
PI3K/AKT in these cell lines. This novel interaction may have clinical relevance 
as immunohistochemical analysis of ER-positive breast cancer patient samples 
revealed IRS-1 Y612 expression positively correlated with total erbB3, p-AKT 
and Ki67 expression. Importantly, we found that recruitment of IRS-1 by erbB3 
impaired IRS-1 recruitment by IGF-IR in both MCF-7 and T47D cells, whilst 
blockade of IGF-1R enhanced erbB3/IRS-1 interaction and sensitised both cell 
lines to HRGβ1. Consequently, blockade of erbB3 signalling enhanced the 
eff  ects of IGF-IR inhibition in these cells. In conclusion, these and previous 
fi  ndings suggest that IRS-1 can be recruited to IGF-1R, EGFR and erbB3 in 
ER-positive breast cancer cells and this may provide an adaptive resistance 
mechanism when these receptors are targeted individually. Consequently co-
targeting of IGF-IR and erbB receptors may prove to be a more eff  ective strategy 
for the treatment of ER-positive breast cancer.
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Based on protein expression profi  les of core regulatory proteins involved in the 
G1–S and G2–M phase transitions, we have identifi  ed three distinct cell cycle 
phenotypes in a series of 200 breast cancers: a G0 out-of-cycle state (18% of 
cases); a G1 arrested/delayed state (24% cases); and accelerated S-G2-M phase 
progression (58% of cases). The accelerated cell cycle progression phenotype 
had a higher risk of relapse when compared with G0 and G1-delayed/arrested 
phenotypes (HR = 3.90 (95% CI = 1.81 to 8.4), P <0.001) and was associated with 
Her2 and triple negative subtypes (P <0.001). High-grade tumours with the G1-
delayed/arrested phenotype showed an identical low risk of relapse compared 
with well-diff  erentiated G0 tumours. In addition to its prognostic signifi  cance, 
the cell cycle phenotype also impacts on individualised therapeutic decisions. 
Only patients showing the actively cycling, aggressive cell cycle phenotype 
are likely to benefi  t from conventional chemotherapeutic S-phase-directed or 
M-phase-directed agents or from the new generation of targeted cell cycle 
inhibitors that are now entering clinical trials.
The DNA replication initiation factor Cdc7 is an emerging anticancer target. 
Cdc7 inhibition results in an abortive S phase and potent cancer cell killing. 
Specifi  city is based on normal cells undergoing a reversible G1 arrest following 
Cdc7 inhibition due to activation of a novel cell cycle checkpoint that is lost 
or impaired in cancer cells. Our analysis of the molecular circuitry underlying 
this replication origin activation checkpoint reveals that G1 arrest is dependent 
on three nonredundant checkpoint axes coordinated through the Forkhead 
transcription factor FoxO3a and p53. We show that only breast cancers 
displaying the accelerated cell cycle phenotype express elevated Cdc7 levels 
and are therefore highly represented in p53 mutant Her2-subtype and triple 
negative tumours. Breast cancers of the luminal subtype expressing low levels 
of Cdc7 undergo a cytostatic G1 arrest after Cdc7 inhibition due to their p53 
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contrast, Her2 and triple negative tumours show a marked response to Cdc7 
inhibitors with potent cancer-cell-specifi  c killing as a result of overexpression of 
the target protein and a result of impairment of the origin activation checkpoint 
due to p53 lesions.
We have thus defi  ned a new therapy and a means of assessing response.
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Peripheral blood T cells can be genetically targeted against cancer using fusion 
receptors known as chimeric antigen receptors (CARs). Many preclinical studies 
have provided great encouragement for this approach. However, pioneering 
clinical trials have been less successful and identifi  ed poor T-cell survival in 
patients as a crucial limiting factor. To address this, what is needed is a system 
to achieve selective expansion of tumour-specifi  c eff  ector T cells, both in vitro 
and in vivo. Here, we describe such an approach using IL-4, a pharmaceutical 
that has been tested in cancer patients and which is normally a poor mitogen 
for T cells. A chimeric cytokine receptor named 4αβ was engineered in which 
the IL-4 receptor α (IL-4Rα) ectodomain was fused to the shared βc subunit, 
used by IL-2/IL-15. Addition of IL-4 to 4αβ-expressing T cells resulted in selective 
phosphorylation of STAT3/STAT5/ ERK, mimicking the actions of IL-2 or IL-15. 
Using receptor-selective IL-4 muteins, partnering of 4αβ with γc was implicated 
in these fi  ndings. Next, human T cells were engineered to co-express 4αβ with 
CARs specifi  c for two breast cancer targets: MUC1 or the extended ErbB family. 
These T cells exhibited an unprecedented capacity to undergo IL-4-dependent 
expansion  in vitro and repeatedly destroyed breast cancer cultures, greatly 
exceeding the performance of IL-2-stimulated cells. Importantly, 4αβ-expressing 
T cells retained cytolytic specifi  city for target antigen and dependence upon 
IL-4 (or IL-2) for survival. We have also used this system to achieve rapid IL-4-
driven ex vivo expansion and enrichment of CAR+ human T cells in bags (T-bags). 
Experiments were performed under closed and pseudo-good manufacturing 
practice conditions, scaling up for phase 1 clinical trials. T cells expanded in this 
manner demonstrate Th1 polarisation and potent tumour destructive activity, 
both in vitro and in vivo, in tumour-bearing SCID Beige mice. Together, these 
fi  ndings provide proof of principle for the development of pharmacologically 
regulated T-cell immunotherapy for breast and other cancers.
P52
Radiotherapy fraction size sensitivity is modulated by DNA repair 
systems
N Somaiah1, J Yarnold2, F Daley1, A Pearson2, K Rothkamm3, T Helleday1
1Gray Institute for Radiation Oncology & Biology, Oxford, UK; 2Royal Marsden 
Hospital and Institute of Cancer Research, Sutton, UK; 3Health Protection Agency, 
Centre for Radiation, Chemical & Environmental Hazards, Chilton, UK
Breast Cancer Research 2010, 12(Suppl 1):P52 (doi: 10.1186/bcr2549)
Introduction There is level I evidence that breast cancers are signifi  cantly more 
sensitive to fraction size than previously thought, so that small fractions spare 
the cancer as much as the dose-limiting normal tissues. In skin, sensitivity to 
fraction size is associated with the proliferative status of cells in the basal 
epidermis, which are more sensitive to fraction size during the fi  rst 3 weeks of 
radiotherapy (RT) than during weeks 4 and 5. This study exploits RT-induced 
proliferation in human epidermis as a model of human cancer to investigate 
changes in DNA double-strand break (DSB) repair pathways postulated to 
determine RT fractionation sensitivity.
Methods Thirty patients prescribed 50 Gy/25 fractions over 5 weeks to the 
breast after tumour excision of early breast cancer were recruited. Then 4 mm 
punch biopsies of breast skin were collected 2 hours after the fi  rst fraction from 
irradiated and contralateral breast, and 2 hours after the fi  fth fraction and 1 hour 
before and 2 hours after the fi  nal fraction from irradiated breast. Formalin-
fi  xed paraffi   n-embedded sections of epidermis were co-stained for β1-integrin 
(epidermal stem cells), Ki67 (proliferation), 53BP1 (DSBs), RAD51 (homologous 
recombination), cyclin A (S–G2 phase) and p21 (cell cycle arrest).
Results The population of β1-integrin+Ki67+ cells shows a drop from baseline by 
day 5 of RT, followed by a signifi  cant increase by day 33 (P = 0.001). All epidermal 
cells show 53BP1 foci following RT, but RAD51 foci are present only in a subset 
of Ki67-expressing cells. Between days 1 and 33, there is a fourfold increase (P = 
0.001) in the fraction of Ki67+ cells carrying RAD51 foci in the basal epidermis. 
This correlates with the observation that more basal cells are in the S/G2 phase 
of the cell cycle by week 5.
Conclusions  Accelerated proliferation in the epidermis at the end of a 
5-week course of fractionated RT is associated with an increased adoption of 
homologous recombination  for repairing DSBs. Adoption of homologous 
recombination, with its high fi  delity, off  ers a mechanism explaining loss of 
fractionation sensitivity in rapidly proliferating normal (and malignant) cells.
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Introduction  Opticin, a novel extracellular matrix glycoprotein, is a major 
component of the vitreous humour of the eye. The vitreous humour is one of 
the few tissues in the body that is avascular and virtually acellular, and previous 
studies have indicated that opticin contributes to the maintenance of this state 
by inhibition of angiogenesis. The aim of this present study is to investigate the 
eff  ect and mode of action of opticin in suppressing tumour cell proliferation 
and migration in vitro in a panel of breast cancer cell lines and to establish its 
therapeutic effi   cacy in human breast tumour xenografts in vivo.
Methods A replication defective adenoviral vector constitutively expressing 
human opticin was generated. A panel of breast cancer cell lines were infected 
with increasing viral doses and eff  ects on cell proliferation and migration were 
investigated. Inhibition of proliferation was seen in three out of four of the 
cell lines used in a dose-dependent manner. In MDA-MB-231 cells, increased 
apoptosis in the virus-treated cells was observed compared with controls. Virally 
delivered opticin also reduced migration in all the cell lines studied, again in a 
dose-dependent manner.
Results To determine whether opticin directly inhibited tumour cell growth in 
vivo, MDA-MB-231 and MDA-MB-468 cells were implanted intradermally into 
nude mice and tumours allowed to grow to 200 mm before administration 
of opticin (108 plaque-forming units). Vessel density was measured by CD31 
immunohistochemistry and a reduction of up to 38% was seen compared with 
untreated controls. A loss of vessel clarity was also observed. Adenoviral opticin-
treated tumours were also signifi  cantly smaller than controls.
Conclusions These results demonstrate that opticin has potent anti-angiogenic 
and anti-proliferative properties both in vitro and in vivo. Together, the current 
information demonstrates opticin could be considered a novel cancer thera-
peutic in the treatment of solid tumours.
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Introduction  Adjuvant endocrine therapy is recommended for all eligible 
patients with breast cancer for a minimum 5-year period. Durations of therapy 
for a shorter period have worse outcomes for patients. This study examined 
whether women in the community completed the full course of adjuvant 
endocrine therapy.
Methods All women diagnosed and treated for breast cancer in the Tayside 
region of Scotland during the period January 1993 to December 2008 were 
identifi  ed. Information on dispensed prescribing was linked to hospital discharge 
records, breast cancer clinical audit, cancer registry and death certifi  cation for 
each individual. Patients were identifi  ed as starting either aromatase inhibitor 
(AI)  or tamoxifen therapy and their dispensed prescribing analysed to see 
whether they completed a 5-year course.
Results A total of 5,729 women were identifi  ed with an incident cancer within 
the study. Seventy-one per cent were initially prescribed tamoxifen, 8% AIs and 
21% received no adjuvant medication. Nineteen per cent of women started on 
tamoxifen switched treatments, compared with 25% starting AIs. For patients 
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compared with 373 (9%) on tamoxifen. At year 2, an additional 40 (12%) stopped 
AIs and 384 (11%) tamoxifen. For 3-year follow-up, an additional 39 (19%) 
stopped AIs, while 351 (11%) stopped tamoxifen. For patients followed for at 
least 4 and 5 years, respectively, an additional 22 (26%) then 5 (20%) stopped 
AIs compared with 297 (11%) and 316 (16%) patients who stopped tamoxifen.
Conclusions  Large numbers of patients prescribed adjuvant endocrine 
therapy stop medication before completing the recommended 5-year period, 
with approximately 20% stopping in the fi  rst 2 years. This is likely to have a 
detrimental eff  ect on patient outcomes. All patients need to be encouraged to 
continue their medication for the full 5-year recommended period to ensure 
they receive the maximum benefi  t.
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Introduction Breast cancer is one of the most common forms of cancers in the 
UK and aff  ects women of all ethnic groups. The psychosocial impact of breast 
cancer has been well documented. However, the research conducted in this 
area has been primarily focused on mainstream Caucasian women. There is very 
little work within the breast cancer literature that captures the experiences of 
Black and Minority Ethnic (BME) women.
Objective To explore the experiences of breast cancer diagnosis and treatment 
in African, Caribbean and South Asian women in the UK.
Methods  Twenty-three English-speaking breast cancer survivors (11 South 
Asian and 12 Black women) were recruited for this study. The women were 
obtained via snowball sampling and through various cancer-related support 
groups (chain referral sampling). A semi-structured interview was conducted 
with each participant. The interviews were then transcribed verbatim and 
inductive thematic analysis was conducted.
Results Thematic analysis of the data revealed six key themes: dealing with the 
illness as a family, healthcare experiences, body image concerns, social support, 
spirituality and life post cancer. Support and spiritual beliefs were identifi  ed as 
highly important coping mechanisms.
Conclusions While BME women share similar concerns to Caucasian women, 
their experiences are also infl  uenced by cultural-specifi  c concerns. This study 
has important implications for healthcare professionals and recognises the need 
to provide culturally sensitive care and support to BME women, which is tailored 
specifi  cally to their cultural values and beliefs.
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Introduction Intensity of acute postoperative pain is a known risk factor for the 
development of chronic postsurgical pain; severe acute pain independently 
predicts chronic pain up to 1 year after breast cancer surgery [1]. Most studies 
capture acute pain intensity using numerical or verbal rating scales (NRS/VRS). 
The objective of this study was to investigate intensity and characteristics of 
acute postoperative pain, using NRS and verbal descriptors, in the fi  rst week 
after breast surgery.
Methods  A prospective cohort study recruiting from four units in north 
Scotland. The sample was newly diagnosed women with histologically proven 
primary invasive or non-invasive breast cancer requiring mastectomy or wide 
local excision (WLE) with/without axillary clearance or sentinel lymph node 
biopsy. Pain was assessed in the fi  rst postoperative week: mean NRS scores at 
rest and movement; severe pain was defi  ned as NRS >5 [1]. Symptoms of ache, 
discomfort, pain, numbness and altered sensations were recorded.
Results Of 102 patients, mean age 60.5 years (SD 9.7), one-third (n = 34) had 
mastectomy and the remainder had WLE. All had axillary surgery: clearance/
sample/sentinel lymph node biopsy. Mean NRS scores at rest after mastectomy 
and WLE, respectively, were: 1.25 (SD 0.4) vs. 1.15 (SD 0.36) (P = 0.23); scores 
on movement: 1.41 (SD 0.49) vs. 1.15 (SD 0.36) (P = 0.006). Forty-one per 
cent reported severe pain on movement after mastectomy vs.15% after WLE 
(P = 0.01). Twenty-two per cent of women reported altered sensations and 
numbness, mostly in the axilla region.
Conclusions Although mean pain scores were low after surgery, almost one-
quarter of patients reported postoperative numbness or altered sensations. 
Studies of postoperative pain should include assessment of pain character in 
addition to pain intensity.
Reference
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after breast surgery. Pain Med 2009, 4:708-715.
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Introduction As the life expectancy of people with learning disabilities rises, 
so too do cancer prevalence rates in people with learning disabilities. Despite 
the eff  orts of government policies to ensure equal access to improve health 
screening, the uptake for breast mammography within this population still 
remains lower than that of the general population. The purpose of this study 
was to ascertain the knowledge of breast cancer among women with a learning 
disability and to explore their experiences of breast mammography.
Methods A qualitative approach using four focus groups with women with 
learning disabilities was employed, and a semi-structured interview schedule 
aided the process.
Results Associated risks, preventative factors and signs and symptoms of breast 
cancer were extremely limited with their sources of knowledge primarily coming 
from carers or nursing staff  . Positive attitudes towards breast mammography 
were reported; however, these women also described negative feelings of fear 
and anxiety, attributed to a lack of understanding about the screening process. 
Emotional support and information were seen to reduce negative feelings. A 
lack of information and embarrassment were identifi  ed as the main barriers to 
screening. Ongoing support from others such as family members and carers, 
accessible information and health promotion and education were considered to 
be main solutions for encouraging attendance for breast mammography.
Conclusions This study highlights the need for health promotion and education 
for women with a learning disability, their family carers and staff   working with 
this target group in order to enhance the knowledge and awareness of breast 
cancer and screening. This not only will aid in reducing the adverse aff  ects of 
breast mammography but will ensure that informed decisions about breast 
screening are made. More accessible multiformat information for women 
with a learning disability is essential in order to facilitate health promotion and 
education.
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Introduction  Although the majority of tumour cell lines, including breast 
cancer cell lines, are sensitive to the death-inducing ligand and potential cancer 
biotherapeutic TNF-related apoptosis-inducing ligand (TRAIL), most primary 
tumours are TRAIL-resistant. Importantly, doxorubicin, a chemotherapeutic 
agent commonly used in breast cancer, has previously been shown to sensitize 
TRAIL-resistant breast cancer cell lines to TRAIL. Furthermore, using receptor-
selective ligands (patent fi   led by MRC Technology) specifi   c for the TRAIL 
death receptors, TRAIL-R1/TRAIL-R2, we have previously shown that primary 
leukaemic cells isolated from patients with chronic lymphocytic leukaemia can 
be selectively sensitized to apoptosis by combining an a histone deacetylase 
inhibitor (HDACi) with a TRAIL-R1-specifi  c form of TRAIL/TRAIL-R1 mAb.
Methods and results To examine the potency of TRAIL-R1/TRAIL-R2-specifi  c 
ligands in breast cancer, a panel of breast tumour cell lines was employed, which 
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approach of culturing primary breast tumour explants ex vivo to maintain their 
three-dimensional architecture provided a more clinically relevant breast tumour 
model. Importantly, all TRAIL-sensitive breast tumour cell lines responded only 
to a TRAIL-R1-specifi   c form of TRAIL. Despite expressing TRAIL-R1/TRAIL-R2, 
the T47D cell line required initial sensitization by doxorubicin and again 
exhibited selectivity towards apoptosis induced by a TRAIL-R1-selective ligand. 
Crucially, we show that doxorubicin can also sensitize TRAIL-resistant primary 
breast tumour explants to TRAIL-induced apoptosis, while having no eff  ect on 
normal breast tissue. Furthermore, in this ex vivo model, TRAIL combined with 
doxorubicin induced signifi  cantly more apoptosis via TRAIL-R1 than TRAIL-R2.
Conclusions Our results have important implications for the potential treatment 
of breast cancer with TRAIL-based therapeutic agents. We propose that using 
a TRAIL-R1-specifi   c ligand/mAb combined with subtoxic concentrations of 
doxorubicin will selectively target tumour cells and minimise potential side 
eff   ects, such as triggering of TRAIL-induced prosurvival pathways in TRAIL-
resistant primary tumour cells or cardiotoxicity induced by higher concentrations 
of doxorubicin used in monotherapy.
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Microenvironmental factors are fundamental in the regulation of normal and 
tumour breast tissue. Two cell types have been implicated in having opposing 
eff   ects on breast tumour cell behaviour: myoepithelial cells exhibit broad 
tumour-suppressor activity, whilst fi  broblasts frequently promote tumour growth 
and invasion. Previous work has described the development of a physiologically 
relevant three-dimensional  heterotypic culture system containing tumour, 
myoepithelial and fi  broblast cells. The data showed organisation of the cells into 
co-unit structures recapitulating ductal carcinoma in situ breast, with homing 
of myoepithelial cells around luminal cells, and highlighted a central role for 
tumour-associated fi  broblasts in disrupting ductal carcinoma in situ structures. 
This study describes further manipulation of the model to include tumour cells 
that represent the heterogeneity of breast cancer.
MCF-7 (ER+), MDA-MB-468, MDA-MB-231 (basal) and MDA-MB-453 (Her2+) 
were cultured in collagen for 7 days in the presence or absence of normal 
myo  epithelial cells. Gels were fi   xed in formalin, paraffi   n  embedded  and 
immunohistochemistry was performed for a series of markers recognising the 
cell types along with basal polarity and basement membrane proteins.
Initial morphological analysis of the cultures has been performed to assess 
the degree of co-unit formation, based on a visual description of the size and 
shape of the co-units. Co-unit formation has been employed as a representative 
measure of tumour progression as it is known to be a key feature in early 
breast cancer invasion. When cultured alone, MCF-7 and MDA-MB-468 cells 
formed spherical co-unit structures and this was maintained in the presence 
of myoepithelial cells. In contrast, MDA-MB-231 and MDA-MB-453 cells show 
a more scattered appearance. The presence of myoepithelial cells induced 
polarity in the MDA-MB-231 cells and a more ordered appearance.
This study is the fi  rst time that the co-culture of tumour cell populations with 
myoepithelial cells has been investigated in three-dimensional collagen gels 
showing diff  erences in morphology that may relate to tumour progression.
Cite abstracts in this supplement using the relevant abstract number, 
e.g.: Holliday DL, Maltby S, Moss MA, et al.: Modelling breast cancer in a 
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